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1.1 Review of Phase I Clinical Trial Designs
Conventional Phase I clinical trials are designed to determine the maximum dose
of a new therapeutic agent that leads to toxicity in an “acceptable” proportion of
patients. This dose is identified as the maximum tolerated dose (MTD), based on
the implicit assumption of a monotonically increasing relationship between dose and
probability of toxicity. Historically, Phase I trials have been designed with simple
algorithmic approaches, four (A, B, C and D) of which are compared in Storer (1989).
Design A is a traditional “3+3” design in which a cohort of three subjects is treated
with the same dose. Escalation occurs if no toxicities are observed, and the study
is terminated if at least two subjects in the cohort experience toxicity, with the
next lowest dose identified as the MTD. If one subject in the cohort experiences
toxicity, an additional three subjects are treated at the same dose level. If none of
those additional three patients experiences toxicity, escalation occurs; otherwise, the
trial stops, with the next lowest dose identified as the MTD. A major limitation of
this design is that de-escalation is never an option and the study terminates once
two toxicities are observed in a cohort of three or six subjects. Limitations of the




Designs B, C, and D are referred to as “up-and-down” designs because they allow
for de-escalation. In Design B, a single subject is treated at a dose level dj. The
next subject is treated at dose level dj−1 if the previous subject experiences toxicity
or at dose dj+1 if the previous subject does not experience toxicity. If consecutive
de-escalations happen, then the trial stops, and the dose level at the second de-
escalation of the consecutive de-escalations is taken as the MTD. If a study fails
to stop early and reaches its planned sample size, then the dose given to the final
subject or the next lower dose is usually taken as the estimate of MTD depending
on the actual amount and degree of toxicity observed in the last group of evaluated
subjects.
Design C is a variant of Design B, in which two consecutive nontoxic responses
must be obtained before escalation occurs, whereas de-escalation occurs whenever a
toxic response is seen. The rule of identifying the MTD is the same as that of Design
B. Design D is a modified version of Design A, in which de-escalation occurs if more
than one subject in a cohort has toxicity. If a single patient has toxicity, then the
next cohort of subjects is treated at the same dose level.
Storer also proposed a pair of two-stage designs, BC and BD, that combine single-
stage designs. The first stage follows design B until the first toxic response is ob-
served. From the point at which the next subject is entered at the next lower dose
level, the second stage design is implemented with fixed sample size. Storer demon-
strated via simulation that the two-stage designs perform better than the single-stage
designs by comparing the expected fractions of subjects that would be treated at dose
levels above the prespecified threshold percentage of toxicity. Storer also found that
the designs performed well as long as the MTD is not chosen to be too extreme of a
3
percentile (low extreme). However, the designs considered by Storer can have very
poor operating characteristics when starting at a dose far below the MTD. Other
limitations of those designs are that subjects who enroll first in the trial are most
likely assigned to doses with sub-optimal efficacy and the MTD selected at the end of
the study has no general interpretation as an estimate of the dose yielding a specified
toxicity rate.
In order to overcome the limitations of algorithmic Phase I trial designs, O’Quigley
et al. (1990) proposed the Continual Reassessment Method (CRM). CRM is based
upon an assumed model for the association of dose and probability of toxicity and
uses Bayesian methods to adaptively assign a dose to each subject. O’Quigley and
Shen (1996) proposed that maximum-likelihood methods could also be used with
the CRM. However, because maximum-likelihood methods fail to be useful until a
toxicity is observed, the authors suggested a combination of the traditional Bayesian
CRM and their proposed maximum-likelihood CRM. At the beginning of the trial, a
Bayesian framework is useful because it allows prior information to be incorporated
into the study design in the absence of toxicity. However, when the sample size
becomes “large”, eg. greater than 12 (as suggested by O’Quigley and Shen, 1996),
the numerical integrals or Monte Carlo methods necessary in the Bayesian design
become computationally intensive. When at least 12 subjects are enrolled and at
least a toxicity is also observed, it is at this point that maximum likelihood methods
can then replace the Bayesian methods. As the sample size increases, O’Quigley and
Shen (1996) show that the recommended dose level of this hybrid CRM approach
converges to the true MTD. There are other competing designs to the CRM, including
efficient dose escalation with overdose control (EWOC) (Babb et al., 1998), a curve-
free method (CFM) (Gasparini and Eisele, 2000) and the biased coin up-and-down
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design (BCD) (Stylianou and Flournoy, 2002). Rosenberger and Haines (2002) gave
a comprehensive review of the currently available Phase I trial designs.
Even though the proposed CRM approaches are superior to the classical Phase
I design schemes, there are difficulties associated with the use of the CRM. Most
notably, each subject (or small group of subjects) must be followed completely for
toxicity before the next subject or group is enrolled. Although O’Quigley et al.
(1990) proposed a solution to this problem by using the data from fully followed
subjects only, this approach is inefficient because it does not fully utilize the infor-
mation available at the time of evaluation. These difficulties may result in trials of
impractically long duration when a trial is designed to evaluate late-onset effects of
a new therapeutic agent and fully utilize the information available at each time of
evaluation, thereby requiring a long follow-up period for each subject.
Cheung and Chappell (2000) proposed a Time-to-Event Continual Reassessment
Method (TITE-CRM) to overcome the difficulties associated with the use of the
CRM. The CRM assumes a parametric cumulative distribution function (CDF)
F (d, β) to describe the relationship between the dose d and toxicity. The TITE-
CRM extends the CRM by considering a weighted dose-response model G(w, d, β) =
wF (d, β) that monotonically increase in w with constraints G(0, d, β) = 0 and
G(1, d, β) = F (d, β) for all d, β, 0 ≤ w ≤ 1. The weight w is a function of time-to-
event of subjects. Thus the TITE-CRM incorporates the subject’s time in a study
into the model, and fully utilize each subject’s information up to each evaluation time
more efficiently than the CRM. As a result, the TITE-CRM allows subjects to be
enrolled whenever they are available and evaluate the long-term toxicity more natu-
rally, hence significantly shortening a study’s duration without delaying the accrual.
Furthermore, the TITE-CRM approach can be generalized to any Phase I design that
5
involves likelihood-based estimation of a MTD and provides an alternative method
to classical design schemes as practitioners desire.
However, the Phase I studies using the TITE-CRM method just like any conven-
tional dose-finding Phase I studies are inadequate for trials in which the agent is
administered repeatedly over time and evaluation of long-term cumulative effects is
important because the TITE-CRM method like any conventional approaches bases
dose-finding on one, initial administration or course of therapy. To overcome this
shortcoming, Braun et al. (2003) presented a modified version of the TITE-CRM
based on a maximum tolerated cumulative dose (MTCD). Their setting was a bone
marrow transplant trial that planned to determine how many weeks of recombinant
human keratinocyte growth factor (KGF) could be administered while keeping toxic-
ity rates below a desired threshold. Each subject was enrolled on the best estimate of
the MTCD; each time a previously enrolled subject completed his follow-up, the es-
timate of the MTCD was updated and assignments for all currently enrolled subjects
were modified based on whether they were assigned the current MTCD. However,
this approach still considered each schedule as a “dose”, as a result, the subjects who
received an incomplete schedule were only evaluated up to the point of their last fully
completed schedule. Furthermore, due to a period of follow-up after a schedule was
completed, the “doses” overlapped, leading to some ambiguity as to which “dose”
contributed to a late-onset toxicity.
To avoid these limitations, Braun et al. (2005) constructed a new paradigm for
Phase I trial designs that allows for the evaluation and comparison of several treat-
ment schedules, each consisting of a sequence of administration times. This method
uses time to toxicity as the outcome instead of a binary indicator of toxicity, with
the total hazard of toxicity modeled as the sum of a sequence of hazards, each associ-
6
ated with one administration. The goal of this design is to determine the maximum
tolerated schedule (MTS) instead of a traditional MTD. Subject accrual, Bayesian
estimation and outcome adaptive decision-making are done in a sequential fashion
as in classical Phase I trial designs.
As an alternative to the method of Braun et al. (2005), we first propose a paramet-
ric mixture cure model for determining the MTS using adaptive designs in early-phase
clinical trials in Chapter II. We discuss the rationale on how to choose our sectional
Weibull hazard model to allow for the non-monotonic toxicity change pattern, we
then develop an EM algorithm to obtain maximum likelihood estimators (MLEs) of
parameters of interest in this mixture cure model. Based on a pre-specified max-
imum tolerated toxicity level, we define a decision rule on how to determine the
MTS for the next subject entering a trial. Later on, we also implement the proposed
mixture cure model by a Bayesian approach. Via simulations, we demonstrate the
performance of the proposed mixture cure model by both estimation methods.
1.2 Review of Cure Rate Modeling Techniques
The cure rate models have become a very useful tool in biomedical research areas,
such as cancer research and AIDS clinical trials. Cure rate modeling is also a rapidly
developing research area in statistical modeling techniques, statistical inference and
real data applications. The survival analysis invoking the concept of cure rate en-
hances our ability to interpret models in a more meaningful way with more flexibility
in modeling.
A cure model is applicable when it is believed that the survivor function for a
time-to-event random variable plateaus to a non-zero constant and does not decay
to zero. Such a model is applicable in survival data settings when the empirical
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survival curve tends to plateau at a value c ( 0 < c < 1 ) as time increases. Using a
cure model, we assume the subject population is a mixture of two groups: susceptible
subjects who will eventually experience the event of interest and cured subjects who
will never experience the event of interest. The proportion of cured subjects in the
population is called the cure rate. Currently, there are two different approaches to
cure rate modeling: mixture cure models and non-mixture cure models.
1.2.1 Mixture Cure Models
Mixture cure models have been a popular method in parametric analyzing sur-
vival data with cured subjects for decades, starting with the two-component mixture
parametric model of Boag (1949). In this mixture model, one component represents
the survival time distribution for the subjects who experienced the event and the
other component is a degenerate distribution allowing for infinite survival times of
cured subjects. Let T denote a random survival time with population survival func-
tion Sp(t), B denote a binary random variable taking values 1 and 0 with probability
p (event rate) and 1−p (cure rate), respectively, where 1−p = Pr(T = ∞). If we let
S(t) = Pr(T ≥ t|T < ∞) denote the latent survival distribution for the susceptible
group, the population survival function Sp(t) can be represented as
Sp(t | θ) = E[S(t | θ)B] = 1− p+ pS(t | θ), (1.1)
which is a mixture of the survival function of susceptibles S(t) and cure rate p.
Different parametric distributions have been used to model the conditional survival
function S(t), including exponential and Weibull distributions (Berkson and Gage,
1952; Farewell, 1977a) . Nonparametric choices for S(t) have also been considered
in the literature (Taylor, 1995; Kuk and Chen, 1992; Sy and Taylor, 2000 and Peng
and Dear, 2000).
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The effects of time independent covariates on the event rate p and the survival
distribution S(t) can be modeled seperately. Let (Ti, Ci, Zi) be a vector of obser-
vations in which Zi is a vector of time independent covariates, Ti is the length of
follow-up time and Ci is a censoring indicator. Let Bi indicate the cure status for
each subject such that Bi = 1 for susceptible subjects who will eventually have a
event and Bi = 0 for cured subjects. Note that if Ci = 1, then Bi = 1 ; however, if
Ci = 0, then Bi is unknown (latent). The effects of time independent covariates on
the event rate p is usually modeled by a logistic regression where




and β is vector of parameters.
Regarding the survival function for susceptibles, Boag (1949) assumed a lognor-
mal distribution and used maximum likelihood methods to estimate the proportion
of cured subjects and regression coefficients. Berkson and Gage (1952) used a sim-
ilar two-component mixture model of an exponential distribution and a degenerate
distribution to allow for cure rate. Using the method of least squares, they fit their
mixture model to a data set on stomach cancer from the Mayo Clinic. Various
mixture-based cure models have been considered, specifically in the area of mixture
parametric cure models; see also Farewell (1977b), Farewell (1977a). Maller and
Zhou (1996) provided a comprehensive treatment to the topic of cure models, es-
pecially on various parametric failure time regression models, and they also studied
extensively one-sample nonparametric failure time models. Tsodikov et al. (2003)
provided a useful summary on nonparametric work for a homogenous sample by
Maller and Zhou (1996).
Recently, more research work has been focused on the nonparametric or semi-
parametric failure time cure models. Taylor (1995) assumed a model with a logistic
9
probability model for the cure rate and a unspecified failure time process for the
failure times of the susceptibles, which was estimated using Kaplan-Meier method.
Kuk and Chen (1992), Sy and Taylor (2000) and Peng and Dear (2000) considered
semi-parametric Cox proportional hazards models for the failure time process. Li
and Taylor (2002) used a semi-parametric accelerated failure time model for the
failure times. However, because the sample sizes in Phase I trials are relatively small
and insufficient for nonparametric methods performing well, we will not consider
nonparametric methods in our work.
Despite its popularity and advantage, a number of problems are associated with
the mixture cure model approach. One of the problems is identifiability of parameters
in the proposed models, first discussed by Farewell (1986). This problem arises when
there is little information in the data about the tail of the survival distribution, so
that a long-tailed survival curve could mimic the effect of a nonzero probability of
cured subjects. We would have great difficulty in distinguishing the models with high
event rates and long tails of survival functions from low event rates and short tails of
survival functions. Li et al. (2001) showed that the mixture cure model with a general
model for the failure time process is identifiable if a parametric model such as (1.2)
for the event rate is assumed. They also considered other important special cases
of mixture cure models and non-mixture cure models, establishing conditions for
identifiability. Our proposed mixture sectional Weibull hazard model is identifiable
according to their results.
A second problem is that a test for the presence of cured subjects or not is a
nonstandard inference problem in the sense that it is testing at the boundary of the
parameter space. Maller and Zhou (1992) proposed a nonparametric test for the null
hypothesis no cured subject present in the population while Ghitany et al. (1994)
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proposed a likelihood ratio test for the presence of cured subjects when assuming an
exponential distribution for the failure times of susceptibles, which is a parametric
test for the null hypothesis. Vu et al. (1998) extended the likelihood ratio test to a
generalized exponential family. However, the limiting distribution of the likelihood
ratio test under mild regularity conditions is not a standard chi-square distribution,
but instead is a 50-50 mixture of a point mass at 0 and a chi-square distribution with
1 degree of freedom.
1.2.2 Non-mixture Cure Models
Non-mixture cure models are an alternative approach in survival analysis to
account for the cured subjects. In these models (Yakovlev and Tsodikov, 1996;
Tsodikov, 1998; Chen et al., 1999), the probability of cure is incorporated into the
model by assuming a bounded cumulative hazard (BCH), Hp(t). In this model,
Hp(t) ≤ C, where C is the finite limit of Hp(t) as t → ∞. As a result, Sp(t) =
exp(−Hp(t)) is approaching exp(−C) and does not decay to zero as t→∞. Tsodikov
et al. (2003) provided a comprehensive review of these BCH modeling techniques in
cure rate estimation and associated statistical problems. We summarize the main
ideas here.
Let T be the survival time with corresponding population survival function Sp(t).
The bounded cumulative hazard model is given by
Sp(t) = exp(−θF (t)), θ > 0 (1.3)
where F (t) is a CDF of some nonnegative random variable such that F (0) = 0. The
cure rate is Sp(∞) = exp(−θ). Tsodikov et al. (2003) used a series of formulas
demonstrating the relationship between a mixture cure model and a non-mixture
cure model. They also showed that when using nonparametric estimation meth-
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ods, both models can be used equivalently to estimate the cure fraction. However,
this equivalence of estimating cure fractions will vanish if the survival function for
the susceptible is parametrically specified because of the confounding effects by the
parameter θ on both the cure fraction and the survival function for the susceptibles.
Tsodikov et al. (2003) has summarized the three distinct advantages of a non-
mixture cure model over a mixture cure model from their thorough review of modeling
techniques and estimation methods associated with both models: First, a compre-
hensive class of nonlinear transformation models (NTM) can be constructed under
the non-mixture cure model framework to incorporate complex covariate effects in
the regression. The traditional proportional hazards model (PH) is a special case
of this rich class of NTM models. However, the mixture cure model does not have
the PH property for the population hazard function. Therefore, the non-mixture
cure model can be a great tool for studying and testing departures from the PH
assumption. Second, in some biomedical applications, a much more biologically
meaningful interpretation of the results for the data analysis can be presented by the
non-mixture cure model. Third, when developing maximum likelihood or Bayesian
estimation procedures, a naturally technical structure is provided by the non-mixture
cure model.
Regarding the parametric mixture cure models, existing research has used haz-
ard functions that are either monotonically increasing or decreasing or piecewise
constants. These hazard-based parametric models are too restrictive in our setting
because they are not flexible enough to entertain situations where the hazard is non-
monotonic. Therefore, it is desirable to obtain hazard-based models that allow for a
hazard function with changing trends (increase-decrease or decrease-increase) while
retain the simple structure of a parametric model. Shao and Zhou (2004) developed
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a new parametric mixture cure model using a three-parameter Burr XII distribution
for the analysis of survival data with cured subjects. The Weibull distribution is a
special case of the Burr XII distribution; thus, the proposed mixture cure model by
Shao and Zhou (2004) includes the Weibull and exponential mixture cure models as
special cases. Shao and Zhou (2004) demonstrated the proposed mixture cure model
fit the given data substantially better than the existing parametric models. Contrary
to using the Burr XII hazard in our setting, we consider a triangular hazard model
in Chapter III. In summary, a triangular hazard model consists of two piecewise
linear functions as a hazard function for susceptibles. Refer readers to Chapter III
for details. The estimation of the triangular parameters involves the estimation of a
change-point and a boundary point. We develop an algorithm to derive the MLEs
of the parameters and demonstrate the consistency and limiting distributions of the
MLEs.
1.3 Review of Methodology for Change-Point Problems and Boundary
Parameter Problems
The problem of testing for, detecting, and locating a change in the distribution
in a sequence of random variables has been examined by both parametric and non-
parametric methods. Using a parametric approach, Hinkley (1970) was the first to
study the maximum likelihood estimator (MLE) of a unknown change-point in a
sequence of time-ordered observations and recognized the key role of the extremum
of a two-sided random walk in the limiting distribution of the MLE of a change-
point. Hinkley also pioneered the work on inference for change-point parameters
including the bias of parameter estimates and confidence regions for change-points.
Hinkley (1972) later demonstrated that the asymptotic distribution of the MLE of a
change-point is unaffected by the estimation of nuisance parameters.
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Jandhyala and Fotopoulos (1999) extended the work by Hinkley and provided a
more accurate approximation to the asymptotic distribution of the MLE of a change-
point in a sequence of time-ordered observations. They also presented a computa-
tionally more efficient and easier algorithm than that of Hinkley for deriving the
bounds of the asymptotic distribution of the MLE that could be used to derive the
confidence interval for a change-point. Although there are published nonparametric
methods for estimation of and inference for change-point problems (Dumbgen, 1994;
Yao and Huang, 1994; Eubank and Speckman, 1994), we will not consider nonpara-
metric approaches in our research due to the fact that the sample sizes in Phase
I trials are relatively small and insufficient for nonparametric methods performing
well.
Detection and location of a change-point in a hazard function under random cen-
soring has been addressed by parametric, nonparametric and semiparametric meth-
ods. But existing parametric methods focus on a piecewise constant hazard function
for a sample without censoring i.e. the hazard function λ(t) of a failure time variable




λlI(τl−1 ≤ t < τl),
where I() denotes the set indicator function. The change-points 0 = τ0 < τ1 < .... <
τm and the constant hazard rates λl > 0, l = 1, ...,m are unknown. Estimation of the
change-points is a nonregular problem in the sense that the probability density func-
tion (PDF) is discontinuous at the unknown change-points. The published results
for the limiting distributions of the change-point estimates exist only for m = 2 i.e.
one change-point. For one change-point (τ) case, Nguyen et al. (1984) constructed
a stochastic process Xn(t), t ≥ 0 for which Xn(τ) converges to 0, and derived a con-
sistent estimator τ̂ that satisfies Xn(τ) = 0. However, no asymptotic distribution
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was derived. Nguyen et al. (1984) called this estimator a pseudo-maximum likeli-
hood estimator because exact maximum likelihood method was not applicable due
to the unboundedness of the likelihood function. Yao (1986) found a constrained
MLE τ̂ that is consistent, and showed that n(τ̂ − τ) converges in distribution to two
independent random walks that are functions of the unknown parameters τ, λ1 and
λ2.
The one-change-point exponential survival model can be embedded in a much
broader family of densities with an unknown discontinuity point considered by Cher-
noff and Rubin (1956). In Chapter III, we use their results to prove the limiting
distribution of the MLE for the unknown change-point in our triangular hazard
model (See Chapter II for definition of triangular hazard function).
In our triangular hazard model, we also encounter the problem of estimating a
boundary parameter, in which the upper bound on the support of the hazard func-
tion is an unknown parameter. To our knowledge, estimation methods in literature
exist only for the setting in which a parameter θ places a lower bound on the sup-
port of a PDF and defines a family of PDFs with one unknown location parameter
f(t; θ) = f0(t− θ) (θ < t < +∞) under the restriction that f0(t) → αctα−1 as t ↓ 0.
Woodroofe (1972) stated results on asymptotic normality of the MLE when a PDF
is differentiable and the MLE is consistent, and stated that for α > 2, the Fisher
information is finite and the MLE has the same asymptotic properties as regular
MLEs under regularity conditions as stated in Cam (1970). For α = 2, the MLE is
also asymptotically normal (Woodroofe, 1972) and efficient (Weiss and Wolfowitz,
1973), but the convergence rate is O{(n log(n)) 12} instead of the usual O(n 12 ). For
1 < α < 2, the MLE has a non-normal limiting distribution with the convergence
rate O(n
1
α ) (Woodroofe, 1974). Smith (1985) extended these results to distributions
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with nuisance parameters φ. The MLEs of φ and θ are not only consistent and
asymptotically normally distributed but also asymptotically independent. We use
the results of Smith (1985) to prove the limiting distribution of the MLE for the
boundary parameter in our triangular hazard model.
1.4 The Purpose of This Paper and Its Structure
This dissertation develops several classes of parametric models in optimal treat-
ment schedule finding for Phase I clinical trials using sequential designs. Our goal
is to compare the performance of different models by same estimation methods and
the performance of different estimation methods under the same model assumptions.
The discussion is based on multiple nested treatment schedules, each schedule con-
tains multiple administrations. It is organized as follows. In Chapter I, Introduction,
we review the literature pertaining to the research in this dissertation.
In Chapter II, we propose a mixture cure model with sectional Weibull hazard
to evaluate a fixed number of nested treatment schedules to determine the MTS. In
this mixture cure model, we model the event rate using a logistic regression model
and model the conditional hazard function for the susceptible using a combination
of two Weibull distributions to account for the non-monotonic nature of the hazard
of toxicity. We use both maximum likelihood and Bayesian methods to estimate the
parameters of interest. We then compare the performance of the modified maximum
likelihood method to that of the Bayesian approach via simulation studies.
In Chapter III, we develop a maximum likelihood procedure to derive the MLEs
of unknown parameters in a triangular hazard model for a single administration and
prove the asymptotic properties of the MLEs. Then, we extend the results from the
single administration setting to the multiple administration (treatment schedule)
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setting. We develop an additive triangular hazard model to determine the MTS via
maximum likelihood method. We also compare the performance of the triangular
model by the maximum likelihood method to the results by the Bayesian approach
via simulations.
In Chapter IV, we propose a non-mixture cure model for optimal treatment
schedule finding in early-phase clinical trials. We use both maximum likelihood
and Bayesian approaches to estimate the unknown parameters and determine MTS.
In the simulation studies of Chapters II-IV, subject accrual, data monitoring and
outcome-adaptive decision-making are done sequentially through the study.
In Chapter V, we compare the performance of different models by same estimation
methods and the performance of different estimation methods under the same model
assumptions. We also provide practical recommendations based on pros and cons of
the proposed models. We conclude Chapter V with a list of selected future research
areas.
CHAPTER II
A Mixture Cure Model for Optimal Treatment Schedule
Finding
2.1 Motivation
Our motivating example is that described in Braun et al. (2005). Specifically, in a
Phase I trial of allogeneic bone marrow transplant (BMT) recipents, the investigators
were interested in how long recombinant human keratinocyte growth factor (KGF)
could be administered as prophylaxis for graft-versus-host disease (GVHD). During
the study, each patient received 60mg/kg of KGF on each of the 2 days prior to
BMT, and on the day of BMT. After 4 days of rest with no KGF, the patient received
KGF for 3 more days. Therefore, KGF was administered using the 10-day schedule
(3-days-on/4-days-off/3-days-on), which is denoted by (3+, 4-, 3+). Toxicity was
monitored for 28 days, motivated by the assumption that any adverse effect due to
a single adminstration of KGF is certain to occur within 18 days. Although one
course of KGF using the (3+, 4-, 3+) schedule is proved to be safe, the investigators
believed that this may not be sufficient prophylaxis for GVHD, which may take up
to roughly 100 days after BMT to develop. For safety concerns, the investigators
wished to evaluate multiple courses of KGF with 4 days of rest between consecutive
courses, and follow up subjects for 100 days.
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Braun et al. (2005) proposed a new method for the motivating example that took
an existing MTD and sought to determine how long that dose could be administered
to subjects without causing unacceptable cumulative toxicity. This method used the
subject’s time to toxicity as the outcome, with the hazard of toxicity modeled as
the sum of a sequence of hazards, each associated with one administration. The
hazard of toxicity attributed to a single administration was modeled by a triangular
function.(See Figure 2.1)
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However, the underlying survival distribution specified in this model was improper
in the sense that the cumulative distribution function (CDF) F (t) 9 1 as t→ +∞.
As a result, the survival function S(t) → c > 0 as t → +∞, in which this survival
fraction c is referred to as the cure rate. As an alternative, we propose to model the
19
cure fraction explicitly and adopt a mixture cure model for the latent survival time.
Furthermore, the survival function S0(t) for susceptible subjects should approach
0 as t→ +∞. So we propose to model the hazard of toxicity as a combination of two
Weibull distributions to account for the changing pattern of the hazard (increase to
maximum then decrease) during a trial. (See Figure 2.2)




































In this chapter, we first consider a mixture cure model for the single administration
setting. We then extend the mixture cure model to the setting of multiple schedules
with the goal of estimating the probability of toxicity occurring within a pre-specified
follow-up period in a trial, allowing for administrative censoring of partially followed
subjects. We use both maximum likelihood and Bayesian approaches to estimate
parameters of interest in maximum tolerated schedule (MTS) finding in this chapter.
Then we compare the simulation results using the maximum likelihood method to
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those using the Bayesian approach.
2.2 Single Administration Setting
2.2.1 Notation and Model Specification
Let tcur denote any given time from the beginning of a trial when the evaluation
of the data is conducted and ncur be the number of subjects enrolled in the trial
at time tcur. Let T ∗i , i = 1, 2, . . . , n, denote the true, possibly unobserved toxicity
time for subject i and tarii be the entry time for subject i. Since the evaluation is
administrative, the assumption of the independence between T ∗ and tcur − tarii are
valid. At evaluation time tcur, the amount of time that subject i has been observed
is denoted by Ti where Ti = min(T
∗
i , t
cur − tarii ) and the indicator of whether or not
a subject is observed with a toxicity prior to time tcur is denoted by Ci where
Ci =
 1 ; T
∗
i ≤ tcur − tarii ,
0 ; T ∗i > t
cur − tarii .
Let Bi indicate whether or not a subject i would eventually have a toxicity in a trial
with infinite follow-up i.e.
Bi =
 1 ; subjects who will have a toxicity0 ; subjects who will not have a toxicity
Thus, Bi = 1 for subjects for whom Ci = 1 as well as a portion of subjects for
whom Ci = 0. In other words, the value of Bi is latent for censored subjects. We say
subjects are susceptible for having a toxicity if Bi = 1 and denote p as the probability
that Bi = 1. We call p the event rate and (1− p) the cure rate.
Assume the conditional CDF for susceptible i is P (Ti ≤ t|Bi = 1) = F0(t) and
for subjects who are non susceptible at time t is P (Ti ≤ t|Bi = 0) = 0. Then, the
marginal CDF of the time to toxicity Ti for subject i is F (t) = P (Ti ≤ t) = pF0(t).
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Note that this marginal CDF F (t) never reaches 1 and has an asymptote at the event
rate p.
Let h0(t) denote the hazard function at time t attributed to a single administration
for susceptibles. In our setting, we feel it is plausible that as the body metabolizes
the study drug, the hazard of toxicity of the agent increases, reaches a maximum, and
then diminishes as the study drug is cleared from the body. There are few parametric
hazard functions satisfying this pattern, as most parametric hazard functions assume
a monotonic pattern. There exist a class of parametric lifetime hazard functions that
allow for non-monotonicity, known as a Burr XII distribution (Shao and Zhou, 2004).
However, the functional form of Burr XII is quite complicated, making estimation of
its parameters difficult.
As a simpler approach, we assume the hazard of a susceptible is a combination
of two Weibull distributions, one with an increasing hazard and the other with a
decreasing hazard, with a change-point at time t = τ . A natural choice would be the





α1−1 ; 0 ≤ t < τ, α1 ≥ 1, λ1 > 0
α2λ
α2
2 (t− τ)α2−1 ; t ≥ τ, 0 < α2 ≤ 1, λ2 > 0.
However, when α2 < 1, this hazard would approach infinity as t approaches τ from
the right. Such a result is unappealing in our setting as we would like our hazard
to be bounded. Furthermore, the corresponding PDF of this shift hazard model
would also be unbounded. As we plan to use maximum likelihood to estimate the
parameters of interest, the unboundness of the PDF at τ would cause problems for
estimation. Therefore, the shift hazard model is not considered further.
In order for our approach to create a bounded hazard function, we instead try
a combination of two truncated Weibull hazards. This truncated Weibull hazard
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α2−1 ; t ≥ τ, 0 < α2 ≤ 1, λ2 > 0.
However, the CDFs and PDFs corresponding to the two functional forms of h2(t)
are equal at the change-point τ if and only if α1 = α2, λ1 = λ2, which violates our
model requirement of a non-monotonic hazard function, i.e. α1 6= α2.
Therefore, we have chosen to use a sectional model involving two Weibull distribu-
tions, where the first part before change-point τ is a two-parameter (α1, λ1) Weibull
distribution and the second part after τ is a three-parameter (α2, λ2, tτ ) Weibull
distribution where tτ is a shift parameter.





α1−1 ; 0 ≤ t < τ, α1 ≥ 1, λ1 > 0
α2λ
α2
2 (t− tτ )α2−1 ; t ≥ τ, 0 < α2 ≤ 1, λ2 > 0
(2.1)
the corresponding survival function as
S0(t) =
 exp[−(λ1t)
α1 ] ; 0 ≤ t < τ, α1 ≥ 1, λ1 > 0
exp{−[λ2(t− tτ )]α2} ; t ≥ τ, 0 < α2 ≤ 1, λ2 > 0
(2.2)





α1−1 exp[−λα11 tα1 ] ; 0 ≤ t < τ, α1 ≥ 1, λ1 > 0
α2λ
α2
2 (t− tτ )α2−1 exp[−λα22 (t− tτ )α2 ] ; t ≥ τ, 0 < α2 ≤ 1, λ2 > 0.
Therefore, the proposed sectional hazard model is characterized by six parameters
(α1, λ1, α2, λ2, τ, tτ ). In order to reduce number of unknown parameters and simplify
the likelihood function for the part when t > τ , we place constraints on both CDFs
and PDFs that they take a single value at τ . This requirement implies that the two
functional forms of both hazard function h0(t) and corresponding survival function
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S0(t) are equal at τ , thus, the six parameters ( α1, λ1, α2, λ2, τ, tτ ) are constrained
to satisfy the following equations:
exp[−(λ1τ)α1 ] = exp[−(λ2(τ − tτ ))α2 ] (2.3)
α1(λ1)
α1(τ)α1−1 = α2(λ2)
α2(τ − tτ )α2−1. (2.4)
Simplifying the two constraint equalities, we can write τ and tτ as functions of
α1, λ1, α2, λ2




tτ = [(α1 − α2)τ ]/α1. (2.6)
Thus, the two parameters τ and tτ are not directly estimated.
2.2.2 Likelihood Function and Estimation
If we denote φ = (θ, p) where θ = (λ1, λ2, α1, α2), then the likelihood function
for φ is given by









ci [1− p+ pS0(ti)](1−ci), (2.7)
in which (T , C) = {(ti, ci), i = 1, ..., n}.
We first use maximum likelihood to estimate the parameters of interest. During
the estimation process, the component 1−p+pS0(ti) will appear in the denominator
of the score equations whenever ci = 0. Therefore, censored observations complicate
computation of the MLEs.
To simplify the computation, we rewrite the likelihood using partially complete
censored observations. Each censored subject who will eventually have an event
contributes P (Bi = 1)P (Ti > ti|Bi = 1) = pS0(ti) to the overall likelihood while
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the censored subject who will not have an event contributes P (Bi = 0) = 1 − p to
the overall likelihood. Therefore, the likelihood function is changed to the modified
likelihood function (MLF)




ci [(1− p)(1−Bi)(pS0(ti))Bi ](1−ci) (2.8)
where Bi is the latent variable for cure status of each censored subject and (T , C, B)
= {(ti, ci, Bi), i = 1, ..., n}.
Table 2.1. Contingency table showing distribution of subjects.
Censoring Indicator
ci = 1 ci = 0
Observed ti ≤ τ n11 n12 n1.
Times
ti > τ n21 n22 n2.
n.1 n.2 n
Table 2.1 displays the distribution of subjects based on whether they are censored
and whether their follow-up is before the change-point, thus dividing the total sample
of n subjects into 4 groups. The cells contain the frequency counts of subjects in
each group. Let T1 ≤ T2 ≤ ... ≤ Tn1. ≤ τ < Tn1.+1 ≤ ... ≤ Tn be the ordered
observed times in a study from a set of n subjects. We assume the change point τ
lies in [Tn1., Tn1.+1). Let the subscript i index the ordered observed times where i = 1
indexes the earliest observed time and i = n indexes the latest observed time.
The log MLF is written as
`c(θ) = `p(p) + `s(λ1, λ2, α1, α2), (2.9)
where `p stands for the part related to the event rate p and `s stands for the part
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[log(α1) + α1 log(λ1) + (α1 − 1) log(ti)]ci + (2.11)
n1.∑
i=1
{[ci +Bi(1− ci)][−(λ1ti)α1 ]}+
n∑
i=n1.+1
[log(α2) + α2 log(λ2) + (α2 − 1) log(ti − tτ )]ci +
n∑
i=n1.+1
{[ci +Bi(1− ci)][−(λ2(ti − tτ ))α2 ]}.
The expectation (E) step of the algorithm (Larson and Dinse, 1985) involves cre-
ating a set of ”pseudo-data” in which the uncensored observations are left intact and
the unit mass associated with each fully censored observation is fractionated and as-
signed to the group of susceptible with a partially complete pseudo-observation. The
fractional mass assigned to each pseudo-observation gi is the conditional probability
that the subject will eventually have a toxicity given that no toxicity has occurred
by time t:
P (Bi = 1|Ti > t) = pS0(ti)/(1− p+ pS0(ti)).
The gi, which will be used in the maximization step, is calculated as the expectation
of Bi given the current estimates of α1, λ1, α2, λ2, τ, tτ :
gi = E(Bi|p̂, α̂1, λ̂1, α̂2, λ̂2, τ̂ , t̂τ , ti, ci),
The maximization (M) step of the algorithm involves calculating the parameter
values that maximize the log MLF of the pseudo-data, i.e. replacing Bi by gi in log
MLF (2.10) and (2.11). Separate optimization procedures are used to find the values
of (α1, λ1, α2, λ2) that maximize ls under constraints (2.5) and (2.6) and the value of
p that maximizes lp.
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The EM algorithm is an iterative procedure that begins by choosing initial es-
timates of (α1, λ1, α2, λ2, p), such as those obtained by ignoring the censored ob-
servations. At each subsequent iteration, the algorithm’s E-step treats the current
estimates of (α1, λ1, α2, λ2, p) as known in order to update each estimate of gi, and
then the M -step treats the current gi values as known and updates the estimates of
(α1, λ1, α2, λ2, p). The convergence criteria can be based on relative changes in the
parameter estimates or the log likelihood values over successive iterations.
We use the following method to select initial values for the iteration procedure.
Let X = log(T ), u = −log(λ1), and b = α1−1. Then X has an extreme-value








b );−∞ < x < log(τ), 0 < b ≤ 1,−∞ < u <∞.
We can derive initial guess estimates of u and b by plotting the product-limit survivor
function Ŝ(x) against x based on observed data. If log[− log Ŝ(x)] is plotted against
x for x < log(τ) (τ can be chosen as the median observed time point) , then u and b
can be estimated from the intercept and slope of a straight line that the plot should
approximate if the extreme value model is appropriate. Denote these estimates as
u1 for the intercept and b1 for the slope, leading to the initial values for (α̂1, λ̂1)
as (b1
−1, exp(−u1)). The initial values for (α̂2, λ̂2) could be estimated in a similar
fashion since the constraints are placed on the survival function S0(t). Since the
threshold of the probability of toxicity which is defined in next section is known, we
use that as the initial estimate for p̂.
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2.3 Multiple Schedule Setting
2.3.1 Notation and Model Specification
We assume that k treatment schedules, s(1), ..., s(k), are investigated in a trial
where s(j)=(s1, s2, ..., smj) and that the jth schedule has a total of mj administra-
tions. Furthermore, s(j) is nested in s(j+1) for each j = 1, ..., k − 1, so that the
duration of a treatment schedule increases with j and m1 < m2 < ... < mk. In our
motivating example, one course of the (3+, 4-, 3+) schedule corresponds to s(1) =
(1, 2, 3, 8, 9, 10), two courses corresponds to s(2) = (1, 2, 3, 8, 9, 10, 15, 16, 17, 22, 23, 24) =
(s(1), s(1) + 14), and so on, with BMT at day 3 in any case.
Let si = {si,1, ..., si,m} denote the consecutive times at which the ith subject re-
ceives an administration, where si,1 coincides with subject’s study start time. Let
mi denote the number of administrations received by subject i at interim study time
t. Although mj administrations are planned for schedule s
(j), at time t it may be
the case that mi < mj either due to administrative censoring or because subject i
had toxicity at time si,mi ≤ t and thus received no further administrations. Let ω
denote the fixed maximum length of follow-up for a trial. ω should be chosen by
the medical investigators for clinical reasons, but must be large enough to accom-
modate the longest schedule, sk. In our motivating example, ω = 100 days. A fixed
target probability pω is elicited from the physicians and is defined as the threshold
probability of toxicity at the given follow-up time ω.
Conditional Hazard Model
Let h0(t|θ) be the hazard function attributed to a single administration for the
subjects in susceptible group, where θ is the parameter vector (α1, λ1, α2, λ2). See
equation (2.1). We define the total hazard of toxicity at time t for a subject treated
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with h0(u|θ) = 0 if u < 0 and h0(t|θ) defined in equation (2.1). We assume that
the form of h0(.) does not change with successive administrations, although this
assumption can be relaxed. The cumulative hazard function (CHF) up to t for a










The PDF at t for a subject treated with schedule s(k) is
fk(t|θ, s(k)) = λk(t|θ, s(k)) exp[−Λk(t|θ, s(k))]
and the survival function up to t is





Let (Tik, Cik, Bik) denote the follow-up time, censoring indicator and cure status
of the ith subject assigned to schedule s(k), respectively, i = 1, ..., nk where nk is the
number of observations in schedule s(k). Let pk denote the event rate for subjects
assigned to schedule s(k).
Assume the probability of an individual Bik in a susceptible group is modeled by
a logistic regression such that
logit(pk) = β0 + β1k (2.12)
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for k = 1, ..., K where k indexes the administration schedules. We can also model
the event rate as a function of the number of administrations in a given treatment
schedule. In this chapter, we have modeled the event rate as the function of the
number of treatment schedule in the simulation studies.
2.3.2 Likelihood Function and Estimation
Following the similar discussion as in subsection 2.2.2, let θ = (λ1, λ2, α1, α2),
β = (β0, β1), and φ = (θ,β), then the modified likelihood function (MLF) for φ
under multiple schedules is given by







cik [(1− pk)(1−Bik)(pkSk(tik))Bik ](1−cik)
where (T ,C,B) = {(tik, cik, Bik), i = 1, ..., nk; k = 1, ..., K}, and the log MLF is
























The EM estimation procedure for φ is similar to that in subsection 2.2.2, with
some modifications as follows: The fractional mass assigned to each pseudo-observation
gik changes to
P (Bik = 1|Tik > t) =
pkSk(tik)
1− pk + pkSk(tik)
.
and the formula for gik changes from definition of gi accordingly.
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2.4 Trial Conduct
We assume N be the maximum number of subjects enrolled in a trial with each
subject assigned a treatment schedule upon arrival. The first subject is assigned the
shortest schedule, s(1). Each subject is followed for up to ω days, with treatment
terminated if a toxicity is observed. Given a threshold pω for the cumulative proba-
bility of toxicity F (ω|φ, s(k)) by time ω for schedule s(k), we compute the estimated
probability of toxicity by time ω, F̂ = F (ω|φ̂, s(k)) for each schedule k, k = 1, ..., K.
The best schedule is defined as that having F̂ closest to pω and i.e. that minimizing
|F̂ − pω|. This criterion, as a function of treatment schedule, is analogous to the
CRM criterion (O’Quigley et al., 1990) as a function of dose. Using this criterion,
the best schedule is identified using the currently available trial data and is assigned
to the next accrued subject. At the end of the trial, the MTS is defined as the best
schedule based upon the complete data of all N subjects.
To get the trial underway using maximum likelihood approach, we must have
heterogeneity among the responses. In order to ensure the existence of meaningful
MLEs, we will not consider using the likelihood approach until we see toxicities
occur. Furthermore, because we enroll subjects sequentially, very little information
is available at the beginning of a trial. In order to use the maximum likelihood in a
trial, we not only need to observe a toxicity occurs but also need to have a sufficient
sample size. We could use a Bayesian approach coupled with proposed sectional
Weibull model or any forms of standard Up-and-Down scheme (Storer, 1989) to
obtain a sufficient sample of subjects with at least one toxicity response. A simple
and reasonable way is to enroll subjects in cohort of size m ≥ 1 at a time, starting
at the shortest schedule. We escalate to the next schedule if no toxicity is observed
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in the previously accrued cohort of subjects and switch to the likelihood approach
once a toxicity occurs and enough number of subjects are enrolled in the study. In
our application, we found via trial-and-error, 15− 20 subjects is a sufficient number
for using a maximum likelihood method. Regarding the cohort size m, it is set to
1 − 3 in most applications although the larger values of m are possible. However,
an important practical consideration is that larger values of m will slow the speed
of schedule escalation so that the trial will take longer before enrolling subjects on
longer schedules.
In contrast, a Bayesian approach does not require a toxicity to occur and a trial
can start right away with first available subject enrolling the shortest schedule. The
proposed model coupled with a Bayesian estimation method can be used to deter-
mine the schedule assignment for next available subject. Such evaluation/enrollment
procedures continue until all N subjects are enrolled in the trial. The safety precau-
tions described in next few paragraphs are applicable to any trials no matter which
estimation method is used.
Some practical constraints are implemented in our design to minimize the risk of
giving a subject an overly toxic schedule. First, our algorithm determines an updated
MTS each time a new subject enrolls in the trial and assigns the newest subject
to that updated MTS with the constraint of only incremental schedule escalation
allowed. For example, if our algorithm recommends to escalate the schedule, we
escalate only to the next longest schedule, regardless of the actual schedule selected
by our algorithm. We do not put any constraint on schedule deescalation.
Our trial design also implement the constraint to retroactively modify the schedule
of a currently enrolled subject if: (1) the currently estimated MTS is different from
the schedule assigned to the currently enrolled subject and (2) the subject has not
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yet received all of the initially assigned schedule. For example, suppose five subjects
have been enrolled: two on the first schedule, two on the second schedule, and one on
the third schedule. If the sixth subject is enrolled and assigned to the third schedule
and a week later the fifth subject experiences toxicity, the algorithm can reduce the
sixth subject’s assignment to the second schedule if the proposed method determines
such a modification is necessary. The number of subjects impacted by such potential
reassignments depends upon the rate of accrual. During rapid accrual, a potentially
larger number of subjects may be reassigned to a different schedule because they will
have been enrolled before full observation of previously enrolled subjects is completed.
During slow accrual, however, the number of reassignments will be minimal because
previously enrolled subjects will have been monitored for the full observation period.
The TITEr-CRM design in Braun et al. (2003) is the first study design to allow
for dose reassignment, regardless of how many subjects actually have their dose reas-
signed. Our approach is an extension of their method in multiple schedule scenario.
In our case, each new schedule of the experimental agent is given over weeks rather
than hours or days, this approach can incorporate new information regarding the
safety profile of the agent in time to modify a schedule assignment during the treat-
ment of an individual patient. This practical consideration is not discussed in other
Phase I trials ( e.g. Cheung and Chappell, 2000; Braun et al., 2005).
Note that all future planned treatment for a subject is stopped once a toxicity
occurs. Thus, a toxicity is assigned to the schedule last administered when the tox-
icity occurred. For example, if a subject is assigned to schedule 3, but experiences
toxicity while receiving schedule 2, the toxicity is assigned to schedule 2. Further-
more, a toxicity is prescribed to the originally assigned schedule if a subject has fully
received his or her originally assigned schedule and then experiences toxicity during
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the posttreatment follow-up period.
2.5 Estimation and Schedule Finding by Bayesian Approach
As a competing alternative to the maximum likelihood method in optimal sched-
ule finding using the proposed mixture cure model, we use a Bayesian approach in
this section. Our schedule-finding algorithm begins with independent informative
priors for αs, λs and βs. The informative priors may be obtained either based
on historical data from previous single administration studies or by elicitation from
the investigators. Since the posterior distributions can not be solved analytically
under the assumed model, Markov chain Monte Carlo (MCMC) technique is used
to compute the posterior quantities. Specifically, a Metropolis-Hastings algorithm
((Robert and Casella, 1999; Gelman et al., 2004) is used. We experimented with
different starting values and were convinced that the chains converged and covered
the entire posterior distribution using multiple sequences and plots. We eliminated
a total of 1000 iterations as burn-in and then generated additional 3000 samples for
summarization.
2.5.1 Priors Based on Historical Data
If dose-toxicity data for a single administration are available from previous studies,
these data may be used to obtain the priors in the multiple schedule trials. Denote
the time of ith subject in the historical trial and the toxicity indicator of this subject
by (Thi, Chi) and Dh = {(Thi, Chi), i = 1, 2, ...nh}, where nh is the number of subjects
in the historical trial. Then the likelihood function of the available historical data is









chi [1− p+ pS0(thi)](1−chi),
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If we assume a vague prior on all parameters of interest before the historical data
are observed, then the posterior of φ given the historical data is then f(φ | Dh) ∝
Lh(φ | Dh) and the prior used at the start of the schedule-finding trial is f(φ | Dh).
The informative priors based on historical data in cure model setting have been
studied extensively by Chen et al. (1999). We refer readers to their work for more
details.
An alternative way of using the available historical data to define priors is to
estimate the parameters of interest using either Bayesian or maximum likelihood
methods. With maximum likelihood methods, we can compute estimates of each
parameter, as well as variance estimates of those parameter estimates. We then set
the mean of the prior distribution at the parameter estimate and the variance of the
prior distribution at the variance estimate. With Bayesian methods, we first select a
prior distribution for the parameters and then combine it with the historical data to
derive posterior mean and variance for each parameter. We then set the mean of the
prior distribution at the posterior mean and the variance of the prior distribution at
the posterior variance. We let µ̂∗ and σ̂
2
∗ denote the respective mean and variance of
the prior distribution for a parameter of interest derived from the historical data as
described earlier where ∗ stands for each of parameters α1, λ1, λ2, β0, and β1.
We then select specific functional forms for the prior distributions. Because α1 >
1, we assume α1 − 1 has a gamma distribution with parameters (c1, d1) such that
α1 has mean c1/d1 and variance c1/d
2
1. Given the prior mean and variance of α1





c1 = (µ̂α1 − 1)2/σ̂2α1 and d1 = (µ̂α1 − 1)/σ̂
2
α1
. Since 0 < α2 < 1, we assume 1/α2 − 1
follows a gamma distribution with parameters (c2, d2) and we use the same approach
as that used with α1 to solve for the actual values of c2 and d2.
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Since both λ1 and λ2 are positive, to simplify the prior selection, we reparameterize
equation (2.1), letting γi = log(λ
αi
i ) i = 1, 2. As γi may be any real number, we
assume γi follows a normal distribution N(µγi , σγi). We then set µγi at the parameter
estimates and σγi at the variance estimates.
Furthermore, if dose-toxicity data for a single course consisting of multiple admin-
istrations are also available from previous studies, then these data can also be used
to obtain the priors on β in addition to the αi, λi, i = 1, 2 in the multiple schedule
trials. Following similar arguments as above, we assume βi, i = 0, 1 follows a normal
distribution with mean as µ̂βi and variance as σ̂
2
βi
that are derived from the historical
data.
When the individual subject data from trials of the single administration are
available but no data available for a single course, the source for the informative
priors on the parameters of interest can be a mixture of historical data and elicitation
from the investigators. For example, in our assumed model, the priors for αi, γi, i =
1, 2 may be from historical data while the priors on βi, i = 0, 1 are elicited from
investigators.
2.5.2 Elicited Priors
When individual subject data from trials of the single administration or a single
course are not available, informative priors must be elicited from the investigators.
This may be done in various ways, with the particular elicitation method tailored to
the clinical setting and investigators’ level of technical expertise. We employed the
following method in our simulation trials.
With regard to the cure fraction parameters β, we ask the investigators to specify
an a priori value, Pk, for the cumulative probability of toxicity for schedule k, k =
1, 2, . . . , K. Based upon the simple linear regression model E{logit(Pk)} = b0 + b1k,
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we use ordinary least squares to find estimates of b0 and b1; we let µβ0 equal the
estimate of b0 and µβ1 equal the estimate of b1.
With regard to the hazard shape parameters θ, we do not have a specific elicitation
strategy. We do rely on the historic data on single dose. For simulation purpose, we
have set mean values of the prior distributions close to true values.
2.5.3 Calibrating the Prior Distribution for Parameters of Interest
In order for the data to dominate the prior distribution, sensitivity analysis of
priors on parameters of interest is essential. As a result, those initially estimated
hyperparameters still need fine tuning for priors to work in conjunction with the data
to allow the schedule-finding algorithm provide a safe and reliable design.
Recall the priors on αi (i = 1, 2) follow the gamma distribution with parameters
(ci, di). We set ci = aĉi and di = ad̂i. The tuning constant a scales the values of
(ci, di) and modulates the variability of f(αi). In addition, the priors on γi (i = 1, 2)
follow the normal distribution N(µγi , σγi). We set µγi = µ̂γi , σγi = bσ̂γi and b is the
tuning constant. Similarly, the priors on βi, i = 0, 1 follow the normal distribution
N(µβi , σβi). We set µβi = β̂i0, σβi = dσ̂(βi0) and d is a tuning constant used to
modulate the variances of βi, i = 0, 1. By simulating the toxicity times of a small
number of subjects, we can compare the prior means for parameter vector φ to their
respective posterior values and evaluate the effects of a small amount of data on prior
f(φ).
The prior variances can not be made arbitrarily large, as is often done with
Bayesian analysis of large data sets. In any small sample size Phase I trials us-
ing adaptive designs, very few data are available, especially at the beginning of a
trial. If there is substantial prior information over too broad range, then it can not
be overcome by a small amount of data. In our application, undoubtedly, large prior
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variances would severely hinder the algorithm’s ability to assign best schedule during
the trial and select a MTS at the end.
Another consideration of priors’ effect is to examine the predictive probabil-
ity of toxicity F (ω|φ, s(j)) for each schedule s(j) to determine whether the prior
may produce pathological behavior by placing too much of the probability mass of
F (ω|φ, s(j)) near 0 or 1 because the consequent distribution of F (ω|φ, s(j)) determine
which schedule to be identified as MTS.
We have tried different starting values for the Markov chains in the Bayesian
estimation procedures. We also used misspecified priors such that the prior means
are different from the true parameters of interest. The simulation results changed
slightly, but overall, the final conclusions were relatively unchanged. Thus the pro-
posed model is insensitive to the misspecified priors and different starting values as
long as the priors are informative at the beginning of a trial but do not dominate
the data at later points in the trial.
2.6 Application to KGF trial
In this section, we investigate the performance of the proposed mixture cure model
in MTS finding via simulation studies using both Bayesian and maximum likelihood
methods. All results are produced in SAS.
2.6.1 Study Setup
In the motivating example, the investigators wished to study k = 6 treatment
schedules corresponding to 2, 4, 6, 8, 10, 12 weeks of therapy. The maximum period
to monitor toxicity was specified to be ω = 100 days because aGVHD occurs during
the first 100 days after transplant. Per the adaptive design, a schedule is specified for
each subject and the therapy is discontinued if a subject experiences toxicity before
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100 days. The goal is to determine how long a subject can receive the therapy while
controlling the probability of toxicity within a pre-specified follow-up period ω to be
less than or equal to the threshold value pω.
We studied the design with a maximum sample size of 30 patients, which is feasible
in Phase I trials but also sufficient to determine the MTS with reasonable accuracy
demonstrated in our simulations. In each simulation, the subject interarrival times
were assumed to be uniformly distributed from 12 to 16 days. When the maximum
likelihood method was used, at the beginning of the trial, the traditional up-and-
down scheme (Storer, 1989) was implemented. More specifically, three subjects were
assigned to the shortest schedule. If there were no toxicities among the three, then
we escalated to the next longer schedule and assigned additional 3 subjects to this
schedule. As soon as we observed a toxicity and total number of enrolled subjects over
15, we switched to the likelihood approach proposed in this chapter and thereafter
included one subject at a time. We considered 6 therapy schedules, s(1), ..., s(6), in
which s(k) did not have natural units and s(k) = {slk, l = 1, ...,mk} for k = 1, ..., 6.
When the Bayesian approach was used, one subject was assigned to shortest schedule
and the trial started right away.
We examined the design’s performance in nine scenarios using the criterion spec-
ified in trial conduct Section 2.4. In the first six scenarios, schedule s(j) is optimal
under the jth scenario for j = 1, ..., 6. In scenario 7, the MTS was located between
schedule 2 and 3, while in scenario 8, the target schedule (MTS) lay between sched-
ule 3 and 4 but closer to schedule 3. If an existing available schedule is close to the
target schedule, then the proposed method should tend to allocate subjects to that
schedule. If the target schedule lies midway between two available schedules, then
the method tend to allocate subjects to both schedules.
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Furthermore, we examined the design’s performance under model misspecification
case in scenario 9, where schedule 3 was the MTS, but the data was not simulated
from the sectional Weibull model. We assumed the toxicity occurred uniformly over
the interval [10 + 14(j − 1), 10 + 14j] under schedule s(j).
Except in scenario 9, the actual times to toxicity were simulated assuming the
parameter values shown in Table 2.2 under a sectional Weibull model. Table 2.2
also contains the actual probabilities of toxicity by day 100 for each schedule and
the threshold probabilities of toxicity for all scenarios. The convergence criteria for
parameter estimates were based on relative changes in estimated parameter values
and log likelihood values.
Table 2.2. True parameter values of the mixture cure model for simulation studies
True Toxicity Prob of Schedule Threshold Prob
Scenario α1 λ1 α2 λ2 β0 β1 1 2 3 4 5 6 of Toxicity
1 3 0.5 0.3 5 -1.92 0.53 0.20 0.30 0.42 0.55 0.68 0.78 0.2
2 3 0.5 0.3 5 -3.00 0.81 0.10 0.20 0.36 0.56 0.74 0.86 0.2
3 3 0.5 0.3 5 -3.00 0.53 0.07 0.12 0.20 0.30 0.42 0.56 0.2
4 3 0.5 0.3 5 -2.17 0.44 0.15 0.21 0.30 0.40 0.51 0.62 0.4
5 3 0.5 0.3 5 -2.61 0.44 0.10 0.15 0.22 0.30 0.40 0.51 0.4
6 3 0.5 0.3 5 -3.06 0.44 0.07 0.10 0.15 0.22 0.30 0.40 0.4
7 3 0.5 0.3 5 -3.35 0.98 0.09 0.20 0.40 0.64 0.82 0.92 0.3
8 3 0.5 0.3 5 -5.54 1.38 0.02 0.06 0.20 0.50 0.80 0.94 0.3
9 na na na na -3.00 0.53 0.07 0.12 0.20 0.30 0.42 0.56 0.2
We conducted the simulation studies in two different settings. In first setting, the
simulation trials were designed without the constraint of reassigning the treatment
schedule to subjects who have not complete the assigned treatment but are not on
the updated MTS during the course of a trial. We ran the simulations for scenarios
1-8. The results for the first setting are summarized in Tables 2.3 and 2.4. In the
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second setting, the simulation trials were designed with reassigning the treatment
schedule to subjects who satisfied the conditions in the Section 2.4. Simulations
were conducted for all 9 scenarios. The results for this setting are given in Tables
2.5 and 2.6.
Regarding Bayesian approach, the simulation trials were only conducted under the
setting with treatment schedule reassignment. The simulation results are displayed
in Tables 2.7 and 2.8. With regard to the prior distributions for θ and β, we use the
elicited values from the investigators as in Table 2.2. For example, the investigators
supply the values P1 = 0.07, P2 = 0.10, P3 = 0.15, P4 = 0.22, P5 = 0.30, P6 = 0.40,
corresponding to the scenario 6 row in Table 2.2. Thus, they believe the longest
schedule, s(6), is optimal, a belief that leads to a misspecified prior for the first five
scenarios. Similarly, we can use any other row of probabilities of toxicity to specify
the priors for the β as long as the row we choose is the investigators’ belief. From
these elicited values, we used the methods described in Section 2.5.2 to estimate
the mean hyperparameter values µβ0 = −3.0 and µβ1 = 0.45. We set variance
hyperparameter values close to two times of the corresponding mean values so that
σβ0 = 6 and σβ1 = 1. For θ, we set the mean values close to the true values so
that µα1 = 2.9, µα2 = 0.4, µγ1 = −2.0, µγ2 = 0.4 and set the variances close to 1 so
that σα1 = 1, σα2 = 1, σγ1 = 1, σγ2 = 1. After a thorough sensitivity analysis, we
determined that the tuning parameters a = 1.5, b = 0.33 and d = 1/3 to allow the
data to have dominate influence on the posterior of the parameters of interest.
2.6.2 Study Result & Conclusion
Tables 2.3 and 2.4 display the simulation results for the setting without treat-
ment schedule reassignment. Table 2.3 displays the estimated parameter values and
corresponding standard deviations under eight scenarios. Table 2.4 summarizes the
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Table 2.3. Estimated parameter values of the mixture cure model by Maximum Likeli-
hood for setting without treatment schedule reassignment. Each entry is the estimated
parameter value (standard deviation).
Estimated Value of
Scenario α1 λ1 α2 λ2 β0 β1
1 3.48 (1.79) 0.52 (0.125) 0.42 (0.214) 5.98 (1.78) -1.89 (0.97) 0.63 (0.41)
2 3.72 (1.87) 0.49 (0.131) 0.38 (0.189) 5.95 (1.96) -3.47 (1.77) 0.98 (0.54)
3 3.78 (1.96) 0.43 (0.133) 0.37 (0.172) 5.75 (1.78) -3.99 (1.94) 0.73 (0.42)
4 3.96 (1.97) 0.49 (0.146) 0.35 (0.174) 5.89 (1.83) -2.81 (1.74) 0.64 (0.37)
5 3.57 (1.64) 0.48 (0.135) 0.38 (0.183) 5.37 (1.92) -3.13 (1.76) 0.56 (0.31)
6 3.89 (1.76) 0.45 (0.128) 0.36 (0.184) 5.74 (1.94) -3.33 (1.84) 0.63 (0.46)
7 3.51 (1.83) 0.49 (0.142) 0.41 (0.185) 5.68 (2.01) -4.03 (1.92) 1.12 (0.66)
8 3.47 (1.94) 0.43 (0.152) 0.35 (0.186) 6.04 (2.12) -6.03 (1.97) 1.56 (0.97)
frequency of each schedule selected as MTS. The first row of each scenario in Table
2.4 contains the percentages of simulations in which each schedule was identified as
the MTS while the second row of each scenario contains the mean percentages of
subjects assigned to each schedule among the simulations. Note that the percent-
ages in each row may not add up to exactly 100% due to rounding. The parameter
estimates in Table 2.3 are reasonably close to the true values and provide confidence
for us to interpret the results in Table 2.4.
The probabilities of toxicity for neighboring schedules in some of the scenarios
are very close to each other, making it more difficult to identify the target schedule.
Despite this, our maximum likelihood approach recommended the correct schedule
at least 30% of the time in the scenarios we investigated, and within one level above
or below the true MTS 70%− 90% of the time for scenarios 1− 6. Specifically, the
algorithm identified the MTS within one schedule of the true MTS in 96%, 92%,
83%, 80%, 76% and 73% of the simulations in scenarios 1 − 6, respectively. We
also note that the algorithm tends to misidentify the MTS at shorter schedules more
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Table 2.4. Performance of the mixture cure model with 30 patients by Maximum
Likelihood for setting without treatment schedule reassignment. Each entry is the
percentage of schedule selection, with the percentage of patients assigned to that
schedule on 2nd line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 64.9 32.4 2.7 0.0 0 0
51.4 30.6 9.1 6.5 2.4 0
2 35.5 43.7 12.6 8.2 0 0
39.6 40.1 10.3 4.8 2.7 2.5
3 12.9 27.5 35.4 20.5 2.8 0.9
13.5 25.1 31.6 20.4 6.2 3.2
4 2.8 14.1 26.4 34.5 16.7 5.5
7.9 13.7 20.4 29.5 19.3 9.2
5 2.1 8.7 13.8 20.1 34.8 20.5
4.3 14.4 17.1 18.7 26.2 19.3
6 0.5 1.5 7.4 17.7 26.2 46.7
3.4 7.4 11.8 15.2 20.8 41.4
7 15.7 34.8 30.4 13.3 5.8 0.
20.4 31.8 27.2 12.3 7.1 1.2
8 7.5 19.3 33.1 25.2 12.6 2.3
13.3 20.2 29.9 21.8 10.7 4.1
often than at longer schedules, indicating that our constraints in trial conduct were
implemented correctly in the algorithm of selecting the MTS and reflects our desire
to promote patient safety.
Our algorithm performed best in scenarios 1 and 6 when the optimal schedule
existed at either the lowest or highest schedule. Furthermore, 51% and 42% of
subjects were assigned to the true MTS in scenarios 1 and 6, respectively. Although
fewer subjects were assigned to the true MTS in the other scenarios, we still found
that no more than approximately 20% of subjects were assigned to a schedule more
than 1 schedule above the true MTS in scenarios 1-6.
In scenario 7, the target schedule was located between schedules 2 and 3. The
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algorithm still performed well, selecting either schedule 2 or schedule 3 in 65% of
simulations. In scenario 8, the true MTS lay between schedules 3 and 4 but was
closer to schedule 3. Our method picked schedule 3 in 33% of simulations and chose
schedule 4 in 25% of simulations, for a total of 58%. In summary, our algorithm
performed well even in the scenarios the true MTS does not exist among the available
schedules but lies between two given schedules.
Table 2.5. Estimated parameter values of the mixture cure model by Maximum Like-
lihood for setting with treatment schedule reassignment. Each entry is the estimated
parameter value (standard deviation).
Estimated Value of
Scenario α1 λ1 α2 λ2 β0 β1
1 3.97 (1.62) 0.48 (0.121) 0.39 (0.201) 5.70 (1.92) -2.16 (1.02) 0.69 (0.41)
2 3.55 (1.42) 0.45 (0.145) 0.35 (0.193) 6.33 (2.12) -3.32 (1.11) 1.01 (0.52)
3 3.75 (1.45) 0.46 (0.131) 0.35 (0.187) 5.73 (1.87) -3.36 (1.21) 0.76 (0.37)
4 3.86 (1.59) 0.39 (0.136) 0.36 (0.182) 6.01 (2.15) -2.49 (1.36) 0.72 (0.43)
5 3.61 (1.47) 0.43 (0.138) 0.34 (0.191) 5.21 (1.62) -3.25 (1.65) 0.67 (0.41)
6 3.31 (1.45) 0.39 (0.118) 0.39 (0.187) 5.74 (1.85) -3.71 (1.87) 0.71 (0.45)
7 3.58 (1.73) 0.48 (0.147) 0.38 (0.186) 5.85 (1.97) -4.37 (2.23) 1.23 (0.63)
8 4.09 (1.93) 0.47 (0.129) 0.39 (0.193) 5.37 (1.74) -6.35 (2.32) 2.04 (0.92)
We now review the results for the setting with reassignment of treatment schedule.
Table 2.5 displays the estimated parameter values and corresponding standard errors
under eight scenarios. Table 2.6 summaries the frequency of each schedule selected
as MTS and the average percentages of subjects assigned to each schedule among
the simulations. Table 2.5 shows similar results as Table 2.3 while Table 2.6 displays
the results similar to those in Table 2.4. We note that the bias for the estimated
value of α1 is about 20% in scenarios 1 and 8 in Table 2.5. Despite the apparent bias,
our algorithm still recommended the right schedule as MTS over 60% of simulations
in Table 2.6. We suspect that the bias in estimating α1 has little impact on the
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results seen in Table 2.6 because the event rate is captured in p. Furthermore, as the
follow-up time gets longer, the survival function for susceptibles does not contribute
to the overall event rate because F0(t) is close to 1. As a result, as long as the biases
of the estimated β are reasonably small, the estimated probability of toxicity for the
correct treatment schedule should be close to the threshold.
Table 2.6. Performance of the mixture cure model with 30 patients by Maximum Like-
lihood for setting with treatment schedule reassignment. Each entry is the percentage
of schedule selection, with the percentage of patients assigned to that schedule on 2nd
line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 65.8 33.0 1.1 0.0 0 0
53.7 32.5 10.2 2.9 0.6 0
2 30.5 49.7 14.6 3.1 1.7 0.3
31.3 36.1 19.2 8.8 3.4 1.2
3 6.6 22.2 38.2 24.3 6.6 2.1
12.3 27.2 29.8 19.2 8.8 2.7
4 4.2 16.4 23.2 36.2 16.1 3.9
5.7 12.2 25.7 31.6 19.4 5.4
5 3.3 10.4 15.1 17.6 37.2 16.4
5.8 8.9 11.9 26.6 30.4 17.0
6 3.6 4.3 7.2 11.9 24.3 48.7
6.4 9.4 12.9 14.0 16.7 40.6
7 14.4 40.7 31.3 13.6 0. 0.
12.9 37.8 30.6 11.9 5.3 1.5
8 4.7 19.6 35.3 24.4 12.3 3.7
7.4 16.8 28.2 29.6 12.8 5.2
9 10.8 29.5 32.4 21.6 5.0 0.7
13.2 27.8 28.7 18.3 8.4 3.6
Scenario 9 of Table 2.6 displays the performance of our algorithm under model
misspecification, where schedule 3 was the true MTS but the actual times to toxicity
did not follow the assumed additive sectional Weibull model. The results follow the
same pattern as that in scenario 3, where the true toxicity distribution matches that
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of the assumed model. In scenario 9, a lower frequency of identifying schedule 3 as
the MTS than that in scenario 3 is found, as is expected.
Our proposed likelihood approach coupled with sectional Weibull model worked
fairly well in the cases where the toxicity of the treatment schedules are moderate.
If the toxicity levels are very small for the shorter schedules or most of the schedules
or too high for the longer schedules, then the likelihood approach may not be a good
choice because the true values of those parameters may be close to the boundary of
the parameter space.
Table 2.7. Estimated parameter values of the mixture cure model by Bayesian ap-
proach for setting with treatment schedule reassignment. Each entry is the estimated
parameter value (standard deviation).
Estimated Value of
Scenario α1 λ1 α2 λ2 β0 β1
1 3.21 (0.534) 0.37 (0.080) 0.39 (0.069) 3.73 (1.539) -2.21 (0.509) 0.58 (0.145)
2 2.87 (0.542) 0.49 (0.112) 0.38 (0.067) 4.80 (1.055) -3.34 (0.413) 0.86 (0.092)
3 2.88 (0.455) 0.44 (0.141) 0.39 (0.077) 4.53 (1.269) -3.44 (0.478) 0.63 (0.126)
4 3.02 (0.305) 0.41 (0.071) 0.39 (0.093) 4.45 (1.596) -2.41 (0.349) 0.58 (0.085)
5 2.79 (0.445) 0.45 (0.143) 0.38 (0.088) 4.62 (1.453) -3.13 (0.365) 0.54 (0.122)
6 2.88 (0.658) 0.48 (0.219) 0.38 (0.059) 4.51 (0.704) -3.56 (0.421) 0.46 (0.123)
7 2.72 (0.632) 0.39 (0.198) 0.37 (0.067) 4.34 (1.233) -3.83 (0.465) 1.05 (0.126)
8 3.07 (0.767) 0.43 (0.286) 0.39 (0.116) 4.45 (1.451) -5.49 (0.896) 1.51 (0.186)
The simulation results by Bayesian approach are displayed in Tables 2.7 and
2.8. The estimated parameter values and corresponding standard deviations for
all scenarios are listed in Table 2.7 while the frequency of each schedule chosen as
MTS are summarized in Table 2.8. Within each scenario, each entry on the first
row in Table 2.8 contains the percentage of simulations in which the given schedule
is identified as the MTS while the entry on the second row contains the average
percentage of subjects assigned to the specified schedule during a trial.
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We note that the parameter estimates in Table 2.7 have smaller biases in most
scenarios compared to those estimates in both Tables 2.3 and 2.5 by the maximum
likelihood method. Furthermore, the standard error estimates in Table 2.7 are smaller
than those in both Tables 2.3 and 2.5 among all scenarios. These results may be
due to the small sample size in our Phase I simulation trials and the informative
priors used in the Bayesian approach. Most importantly, the fact that the parameter
estimates are reasonably close to the true parameter values gives us confidence to
interpret the results in Table 2.8.
Table 2.8. Performance of the mixture cure model with 30 patients by Bayesian ap-
proach for setting with treatment schedule reassignment. Each entry on the 1st row is
the percentage of simulations a schedule chosen as MTS, with the average percentage
of patients assigned to a given schedule on 2nd line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 85.8 11.6 2.6 0 0 0
64.9 18.5 12.6 2.0 1.3 0.7
2 30.6 52.3 11.8 5.2 0.1 0.
25.0 40.1 20.0 12.4 3.3 1.2
3 6.3 19.7 51.8 16.6 5.6 0
11.3 31.1 39.8 10.4 4.1 3.2
4 0 7.3 31.9 41.8 15.3 3.7
5.0 14.4 23.6 39.0 14.7 3.3
5 2.1 10.4 17.4 20.3 40.3 19.5
5.9 8.5 15.3 17.2 34.2 18.9
6 0. 1.8 6.2 13.8 19.8 58.4
4.1 6.3 7.9 14.4 21.5 45.8
7 9.4 41.9 32.7 12.1 3.9 0.
11.6 35.0 31.4 14.1 7.9 0.
8 3.2 11.3 42.8 30.3 9.8 2.6
5.8 17.2 35.9 25.9 10.7 4.5
9 5.8 29.1 41.1 16.1 5.8 2.1
9.8 26.3 32.7 18.9 7.2 5.1
Most important information we can take away from Tables 2.6 and 2.8 is that
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there is no marked difference between the results as final recommendation is con-
cern by two estimation methods. In addition, there is no big difference as far as
final recommendation is concern no matter whether the assumed model is right or
not. However, in scenario 1, the Bayesian approach has a much higher percentage
(15% more) of identifying the optimal schedule 1 as the MTS than the maximum
likelihood method. In scenarios 2-6, the Bayesian approach had a moderately higher
percentage (3% − 10% more) of correctly selecting the optimal schedule (schedule
j for scenario j as true MTS) as the MTS than maximum likelihood method. We
can also say, in scenarios 2-5, both Bayesian and maximum likelihood methods have
similar percentages of choosing the true optimal schedule as MTS. Furthermore, the
pattern of the results in scenario 7 is similar as that in scenarios 2-3. The results in
scenario 8 follow the same pattern as scenarios 3-4.
The results from scenario 9 in both Tables 2.6 and 2.8 demonstrate the effects
of the model misspecification on the MTS identification. We note that the results
in scenario 9 is similar to those in scenario 3, although scenario 3 has a higher
percentage of selecting schedule 3 as the MTS. In summary, both maximum likelihood
and Bayesian approaches work well under model misspecification cases even though
more subjects are assigned to the true optimal schedule when the model is correctly
specified.
Table 2.9. Average number of observed toxicities (out of 30 subjects) in the simulated
trials using the mixture cure model
Estimation Schedule Scenario
Method Reassignment 1 2 3 4 5 6 7 8
MLE No 7.72 6.23 5.65 12.13 10.84 9.32 8.29 7.15
MLE Yes 7.51 6.13 5.57 11.56 10.65 9.67 7.48 6.27
Bayesian Yes 6.80 6.34 5.69 11.83 10.49 9.72 7.85 6.47
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An additional comparison of the safety profiles of the trial implementation with
or without treatment schedule reassignment and by different estimation methods is
found in Table 2.9, which compares the two ways of implementing the trials with
regard to the average number of subjects out of 30 that experienced toxicity in each
scenario. Overall, the rate of toxicities is similar in both implementations (with or
without schedule reassignment), although the rate of toxicities is marginally higher
in the trial without treatment schedule reassignment than the one with it. We also
note that the numbers are very close for both estimation methods. There is no clear
pattern on which method had more observed toxicities among all scenarios. Note
that the average number of observed toxicities were not decreasing from scenario
1 to scenario 6 but were higher in scenarios 4-6 than in scenarios 1-3 because the
probability of toxicity pω = 0.2 for scenarios 1 to 3 while that pω = 0.4 for scenarios
4 to 6.
Table 2.10. Average number of subjects (out of 30 subjects) had treatment schedule
reassignment in the simulated trials using the mixture cure model
Estimation Scenario
Method 1 2 3 4 5 6 7 8 9
MLE 0.89 1.86 3.79 5.05 6.59 7.46 2.17 4.31 4.28
Bayesian 0.43 1.39 4.46 5.73 6.97 7.63 3.08 6.23 3.58
An interesting information regarding the average number of subjects out of 30 who
had treatment schedule reassignment is listed in Table 2.10. Overall, the numbers
of subjects who went through treatment reassignment are higher in the scenarios
where the longer schedules were the true MTS. The numbers are comparable for
both methods with no apparent trend across all scenarios. For example, in scenario
3, four subjects experienced treatment reassignment when maximum likelihood used
while five subjects had schedule reassignment when Bayesian approach used. On
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the contrary, in scenario 9, four subjects experienced treatment reassignment when
maximum likelihood method used but only three subjects had schedule reassignment
when Bayesian approach used.
In this chapter, we proposed a mixture cure model with sectional Weibull distri-
butions to evaluate a fixed number of nested treatment schedules to determine the
MTS, in which we modeled the event rate by a logistic regression and modeled the
conditional hazard function for the susceptible with a combination of two Weibull
distributions to account for the non-monotonic nature of the hazard of toxicity. We
used both maximum likelihood and Bayesian approaches to estimate parameters of
interest. We performed simulation studies to investigate the performance of our pro-
posed model in identifying MTS and found that our proposed model performed well
in the scenarios we investigated.
CHAPTER III
A Triangular Hazard Model for Optimal Treatment
Schedule Finding
3.1 Motivation
Recall the motivating example in Chapter II. In this setting, Braun et al. (2005)
proposed a new Phase I trial design with parameter estimation based upon Bayesian
methods. In this chapter, we will explore parameter estimation of the triangular
hazard model proposed in Braun et al. (2005) via a maximum likelihood method.
We will also derive the large sample properties of the MLEs when all subjects receive
a single adminstration. Then we will compare the performance of the optimal treat-
ment schedule finding by the maximum likelihood to that by the Bayesian approach
under the setting with treatment schedule reassignment.
3.2 Single Administration Setting without Censoring
3.2.1 Notation and Statistical Model
Let Ti, Ci, i = 1, 2, . . . , n, be the same notation as in section 2.2.1 for subject i.








; 0 < t ≤ θ1, θ1 > 0, θ2 > 0
θ2(θ3−t)
θ3−θ1 ; θ1 < t ≤ θ3, θ1 < θ3,
0 ; t > θ3, or, t ≤ 0.
(3.1)
where θ = (θ1, θ2, θ3). We can also write the hazard function as h0(t | θ) = θ2tθ1 I(0,θ1]+
θ2(θ3−t)
θ3−θ1 I(θ1,θ3], in which I(a,b] is the indicator that t lies in the open interval (a, b]. We
use a closed bracket to indicate if either endpoint should be included in the interval.
Thus, θ1 denotes the time at which the hazard reaches its maximum, θ2, and θ3
denotes the time when the hazard vanishes to zero. We refer to θ1 as the change-
point of h0(t | θ) and θ3 as the duration of h0(t | θ). See Figure 2.1 in Chapter II for
a plot of the triangular hazard function. Note that the constraint imposed on the
parameters of the triangular hazard model is 0 < θ1 < θ3 < +∞.
Then the corresponding cumulative hazard function (CHF) for Ti is
H0(t | θ) =

0 ; t ≤ 0,
θ2t2
2θ1





2(θ3−θ1) ; θ1 < t ≤ θ3, θ1 ≤ θ3,
θ2θ3
2
; t > θ3
(3.2)
and the corresponding survival function and PDF are
S0(t | θ) = exp[−H0(t | θ)]
f0(t | θ) = h0(t | θ) exp[−H0(t | θ)]
respectively.
Note that the CDF F0(t | θ) = 1−exp(−θ2θ32 ) for t > θ3. F0(t | θ) is not a standard
CDF in the sense that F0(t | θ) 9 1 as t→ +∞. Because a standard CDF is needed
for proving that the score equations for estimating the θs are unbiased, we define
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K(θ2, θ3) be the normalization factor 1− exp(− θ2θ32 ). Then a standard CDF can be
defined as F (t | θ) = F0(t | θ)/K(θ2, θ3) so that F (t | θ) = 1 for t > θ3. Thus, the
standardized PDF f(t | θ) = f0(t | θ)/K(θ2, θ3) is what we choose to work with.
3.2.2 Derivation of MLEs for a Sample without Censoring
We first consider a setting in which no censoring occurs, i.e. Ti = T
∗
i ≤ θ3. Since
the derivation of the MLE of θ will be based upon the ordered observed times
T1 ≤ T2 ≤ ... ≤ Tn, we modify the notation so that i indexes the ordered observed
times where i = 1 indexes the earliest observed time and i = n indexes the latest
observed time. Thus, the likelihood function is given by
Ln(θ | T ) =
n∏
i=1
h0(Ti | θ) exp[−H0(Ti | θ)]/K(θ2, θ3) (3.3)
in which T = (T1, ..., Tn). And the corresponding log likelihood function is written
as






























Q3(θ2, θ3) = n log(θ2)− n log(K(θ2, θ3)).
Because θ1 is the change-point of the PDF f(t,θ), we can not use the score
equation to derive the MLE of θ1. So we consider an alternative approach to derive
the MLE of θ1. In the following theorem, we summarize the result about the MLE
of θ1.
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θ3 − θ1 ), the log like-
lihood function (3.4) attains its maximum at one of the order statistics (T1, ...., Tn).
See the Appendix for a proof. The specific order statistic assigned to MLE θ̂1 will
depend upon the values of the other two parameters. Specifically, let
r̂(θ2, θ3) = arg max
r∈{1,...,n}
{`n(Tr, θ2, θ3)}, (3.5)
then r̂(θ2, θ3) is a function of θ2 and θ3 that can only take the discrete values in [1,
n], thus the MLE of θ1 is
θ̂1 = Tr̂(θ2,θ3) (3.6)
See Figure 3.1 for a pictorial representation of r̂(θ2, θ3). The properties of r̂(θ2, θ3)
are summarized in the following theorems.
Theorem 2. For given θ2, r̂(θ2, θ3) has following properties:
1. r̂(θ2, θ3) is a non-increasing function of θ3
2. limθ3→∞ r̂(θ2, θ3) = 1
3. limθ3→Tn r̂(θ2, θ3) = n
4. r̂(θ2, θ3) is a step function having (n − 1) discontinuity points at θ3,(n−1) <
θ3,(n−2) < ... < θ3,1 in (Tn,+∞).
r̂(θ2, θ3) =

n ; θ3 ∈ (Tn, θ3,(n−1))
n− 1 ; θ3 ∈ [θ3,(n−1), θ3,(n−2))
...
r ; θ3 ∈ [θ3,r, θ3,(r−1))
...
1 ; θ3 ∈ [θ3,1,+∞).
(3.7)
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See the appendix for a proof. Recall from the definition of the triangular hazard
model that θ3 must be finite and greater than θ1. From Theorem 2, we have the
following results: 1) if θ3 = +∞, then θ1 = T1 2) if θ3 = Tn, then θ1 = Tn. As
these two results violate our model assumptions, we put constraints around θ1 and
θ3 such that T1 < θ1 < Tn < θ3 < +∞. To be more precise, T2 ≤ θ1 ≤ Tn−1,
θ3,(n−2) ≤ θ3 ≤ θ3,2 where θ3,(n−2) and θ3,2 are defined in Theorem 2.
Similar properties can also be derived for r̂(θ2, θ3) as a function of θ2 for given θ3
with the exception that
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where r = 1, ..., n−1. In summary, the function r̂(θ2, θ3) can be viewed as a bivariate
step function which has a countable number of discontinuity points. Except those
discontinuity points, the log likelihood function `n(Tr, θ2, θ3) is differentiable with
respect to θ2 and θ3.
We have discussed the estimation of θ1 for given θ2 and θ3. Now, we discuss the
estimation of θ2 and θ3 for given θ1. To simplify the notation, we replace θ1 by the
estimator Tr where r is a function of θ2 and θ3 and we drop the ’hat’ from r̂(θ2, θ3).
The log likelihood function of θ2 and θ3 for given θ1 is defined in equations (3.4),
(A.2) and (A.3).
Let
θ̂2(θ3) = arg max
θ2,n−2≤θ2≤θ2,2
{`n(Tr, θ2, θ3)}. (3.9)
and
θ̂3 = arg max
θ3,n−2≤θ3≤θ3,2
{`n(Tr, θ̂2(θ3), θ3)}. (3.10)
Under the constraints T2 ≤ θ1 ≤ Tn−1, θ2,(n−2) ≤ θ2 ≤ θ2,2 and θ3,(n−2) ≤ θ3 ≤ θ3,2,
using results from Theorem 1 and the score equations of θ2 and θ3, we evaluate the log
likelihood function (3.4) iteratively and yield MLEs as follows: θ̂3, θ̂2 = θ̂2(θ̂3), θ̂1 =
Tr(θ̂2, θ̂3), where θ̂2(.) and r̂(., .) are defined in equations (3.9) and (3.5) respectively.
3.2.3 Consistency and Limiting Distributions of Constrained MLEs for a Sample
without Censoring
We consider the density function f(t | θ) as defined in subsection 3.2.1 with param-
eter θ = (θ1, θ2, θ3) and constraints {T2 ≤ θ1 ≤ Tn−1, θ2,(n−2) ≤ θ2 ≤ θ2,2, θ3,(n−2) ≤
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θ3 ≤ θ3,2} where θ2,(n−2), θ2,2 as defined in (3.8) and θ3,(n−2), θ3,2 as defined in (3.7).
Before stating our main results in this section, we define more notation for later use.
First, let θ0 = (θ1(0), θ2(0), θ3(0)) denote the true value of θ and θ̂n = (θ̂1(n), θ̂2(n), θ̂3(n))
denote the MLEs of θ for sample size n. Second, let θ̂i:j be the MLE of θi given θj
at the true value of θj(0) when i 6= j. We also state one condition and two lemmas.
Condition 1: Assume θ3 is known. For any θ1 6= θ1(0) ∈ [0, θ3], there exists a
δ(θ1, θ1(0)) > 0 such that
Eθ1(0) [sup{log f(t, θ1)− log f(t, θ1(0)) : |θ1 − θ1(0)| ≤ δ(θ1, θ1(0))}] (3.11)
is less than 0.
Lemma 1: θ̂1:3 is consistent under the given constraints and condition 1.
Lemma 2: Let X1, ..., Xn be i.i.d. with PDF g(x) satisfying g(x) = 0 for x < 0
or x > θ3 and g(θ1) = α > 0 where 0 < θ1 < θ3 and var(Xi) = 1. Let X(i) denote
the order statistics in relation to the change-point such that X(−r) ≤ X−(r−1) ≤ ... ≤
X(−1) ≤ X(0) = θ1 ≤ X(1) ≤ ... ≤ X(n−r). Then for any positive integer m ≤ n − r,
{n(X(1) − θ1) > 0, n(X(2) −X(1)), ..., n(X(m) −X(m−1))} converges in distribution to
Y1, ..., Ym where Y1, ..., Ym are i.i.d and Yis are exponential with E(Yi) = α. For any
positive integer m ≤ r, {n(X(−m)−X(−m+1)), ..., n(X(−2)−X(−1)), n(X(−1)−θ1) < 0}
converges in distribution to −Y−m, ...,−Y−1 where Y−m, ..., Y−1 are i.i.d. and Y−i are
exponential with E(Y−i) = α.
We define the following quantities that will be used to define the variances of
limiting distributions.




) log f(T |θ)( ∂
∂θ2
) log f(T |θ)} (3.12)
where Eθ denotes expectation with respect to f(.|θ).
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Part B) For θ3, we can not define m33 in the same way as m22 because θ3 is the
upper boundary of the support for the given PDF. Thus, we adopt the definition of









2(θ3 − θ1)K(θ2, θ3)
(3.13)
where




Definition 2: Let {Yn} be a sequence of random variables and {rn} be a sequence
of positive constants. If
lima→+∞limn→+∞ sup pr(|Yn| > arn) = 0,
then we say Yn ≤p rn.
Definition 3 : Let {Xn} and {Yn} be sequences of i.i.d. random variables which are
exponential with hazard rate 1. Without loss of generality, we assume θ1 ≤ θ3 − θ1,
let ω1 = θ1 log(
θ3−θ1
θ1








where J1 is that value of j (1 ≤ j ≤ n) that minimizes
∑j
i=1(Xi−ω1) and J2 is that
value of j that maximize
∑j
i=1(Yi − ω2). Furthermore, let
ψ =
θ2(θ3 − 2θ1)










−1S1 ≤ −ω2−1S2 − 1
−ψ−1ω2−1
∑J2
i=1 Yi ; otherwise.
(3.14)
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We are in a position to state our main results about the asymptotic distributions
of the MLEs for θ.
Theorem 4. Assume all constraints specified at the beginning of subsection 3.2.3
are satisfied. The values {mii, i = 2, 3} are defined in Definition 1. Then
1. there exist MLEs θ̂n = (θ̂1(n), θ̂2(n), θ̂3(n)) subject to the above constraints such
that
θ̂1(n) − θ1(0) ≤p n−1, (3.15)
θ̂2(n) − θ2(0) ≤p n−
1
2 , (3.16)
θ̂3(n) − θ3(0) ≤p (n log n)−
1
2 . (3.17)
In other words, the MLEs are consistent. Moreover,
θ̂1(n) − θ̂1:3 = op(n−1), (3.18)
θ̂2(n) − θ̂2:1 ≤p (n log n)−
1
2 , (3.19)
θ̂3(n) − θ̂3:1 ≤p n−
1
2 (log n)−1 (3.20)
2. {n(θ̂1(n)−θ1(0)), n
1
2 (θ̂2(n)−θ2(0)), (n log n)
1
2 (θ̂3(n)−θ3(0))} converges in distribution
to a random vector (Z1, Z2, Z3) where (Z1, Z2, Z3) are independent, Z1 is defined
in Definition 3, (Z2, Z3) are normal random variables with common mean 0 and
respective variances m−122 and m
−1
33 where {mii} are defined in Definition 1.
3.3 Single Administration Setting with Censoring
3.3.1 Derivation of MLEs for a Censored Sample
We extend our results from a sample without censoring to data with independent
right censoring. Since the administration censoring in our motivating example is
independent of survival time, the assumption of independent right censoring is valid
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in Phase I clinical trials. Let T1 ≤ T2 ≤ ... ≤ Tr ≤ θ1 < Tr+1 ≤ ... ≤ Tn ≤ ... ≤
TN ≤ θ3 be the order statistics of the uncensored and the censored observed times
from N subjects with common hazard function h(t) as defined in equation (3.1). Let
Tn index the largest uncensored time among all the ordered time points, the change-
point θ1 lies in [Tr, Tr+1) and TN+1 is +∞. In addition, θ1 must be less than TN in
order for θ1 and θ3 to be identifiable. We use the same notation as those in section
3.2.2 to be consistent.














Ci [K − 1 + S0(Ti)]1−Ci (3.21)
N∏
i=n+1
[K − 1 + S0(Ti)]1−Ci ,
in which T = (T1, ..., TN), C = (C1, ..., CN), and K = K(θ2, θ3). From the
assumptions, we have Cn = 1, Ck = 0 for any k > n. And the log-likelihood
function of the proposed model can be written as
















































Q3(θ2, θ3) = log(θ2)
n∑
i=1
Ci − k log(K(θ2, θ3)),





















Theorems 1 & 2 for a sample without censoring still hold for a sample of inde-
pendently right censored data with some modifications, such as replacing n by N in
Theorems 1 & 2 where the likelihood function is based on (3.21) instead of (3.3).
Similar properties still hold for r̂(θ2, θ3) as a function of θ2 for given θ3.
We assume that the location of θ3 in [0, TN+1] is unknown where TN+1 is +∞
and θ3 is greater than the largest observed time point TN . We have identified the
constraints in subsection 3.2.2. The constraints are T1 < θ1 < TN , 0 < θ2 < ∞
and TN < θ3 < ∞. More precisely, T2 ≤ θ1 ≤ TN−1, θ2,(N−2) ≤ θ2 ≤ θ2,2 and
θ3,(N−2) ≤ θ3 ≤ θ3,2, where θ3,(N−2) and θ3,2, θ2,(N−2) and θ2,2 are derived similarly
as in subsection 3.2.2. Barring the points of discontinuity of the function r̂(θ2, θ3),
the log likelihood function `N(θ) is differentiable with respect to θ2 and θ3. We
summarize the maximum likelihood estimation procedure as follows: Using results
from Theorem 1 and the score equations of θ2 and θ3, evaluate log likelihood function
(3.21) iteratively and yield MLEs as follows:
θ̂3, θ̂2 = θ̂2(θ̂3), θ̂1 = Tr(θ̂2, θ̂3),
where θ̂2(.) and r̂(., .) are defined in equations (3.9) and (3.5) respectively.
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3.3.2 Consistency and Limiting Distributions of Constrained MLEs for a Censored
Sample
We consider the density function f(t | θ) and survival function S(t | θ) as defined
in subsection 3.2.1 with parameter θ = (θ1, θ2, θ3) and constraints {T2 ≤ θ1 ≤ TN−1,
θ2,(N−2) ≤ θ2 ≤ θ2,2, θ3,(N−2) ≤ θ3 ≤ θ3,2} where θ3,(N−2) and θ3,2, θ2,(N−2) and θ2,2 are
derived similarly as in subsection 3.2.2.
Since the administration censoring in our motivating example is independent of
survival time, the independent right censoring assumption is valid. Similar definitions
and lemmas as those in subsection 3.2.3 hold under the assumption of independent
right censoring with some modifications, such as replacing (3.11) by
Eθ1(0) [sup{log f
c(t, θ1)− log f c(t, θ1(0)) + logS1−c(t, θ1)− logS1−c(t, θ1(0)) : (3.23)
|θ1 − θ1(0)| ≤ δ(θ1, θ1(0))}]




) log f c(T |θ)S1−c(T |θ)( ∂
∂θ2
) log f c(T |θ)S1−c(T |θ)} (3.24)
in Definition 1 where c is the censor indicator associated with time T. Furthermore,
Similar results as Theorem 4 in subsection 3.2.3 holds for censored samples with
some modifications, such as replacing n by N in Theorem 4.
The rationale is as follows: First, from the estimation procedure, we have θ̂1 = Tr
where Tr is an order statistic from sequence {Ti}Ni=1. The arguments to derive two
independent random walks still apply. Second, extending the asymptotic results of
θ̂2 and θ̂3 from a sample without censoring to censored data follows similar argument
as extending the regular MLE asymptotic properties to censored samples.
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3.4 Numerical Studies
In this section, we investigate the finite sample behavior of the constrained MLEs
for the parameters of interest in the triangular hazard model via simulation studies.
All results were produced in SAS.
We generated 1000 random samples from each of the following two triangular
hazard models: (1) θ1 = 4, θ2 = 0.05 and θ3 = 18, (2) θ1 = 3, θ2 = 0.004 and θ3 = 18.
Uniform censoring times were generated in the interval (0, U) with U selected to give
expected censoring proportion of 0 (no censoring) and 20% (censoring), respectively.
For both censoring proportions, samples of n = 30, n = 50 , n = 100 and n = 200
(where n is the sample size) were generated. The convergence criteria were based
on relative changes of estimated parameter values and log likelihood values. All the
computations of θ̂ were subject to the specified constraints in subsection 3.2.3 and
subsection 3.3.2.
The means of the MLEs and the coverage probability of 95% confidence intervals
for the MLEs θ̂ = (θ̂1, θ̂2, θ̂3) in 1000 replications were computed. The 95% confi-
dence intervals for the MLEs θ̂ = (θ̂1, θ̂2, θ̂3) were calculated based on Theorem 4.
Note that no asymptotic variance estimator is available for the MLE of θ1. Therefore,
no confidence interval is derived for θ̂1.
The simulation results pertaining to the evaluation of θ̂ = (θ̂1, θ̂2, θ̂3) are pre-
sented in Table 3.1, and Table 3.2. We list the mean of MLEs, the mean of asymptotic
standard error (SE), the empirical (sample) SE and the coverage probability of 95%
confidence interval for different sample sizes and censoring proportions.
In Table 3.1, the data were simulated under θ1 = 4, θ2 = 0.05 and θ3 = 18. The
overall performance of the proposed MLEs for the given triangular hazard model is
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Table 3.1. Parameter estimates and their inference with 1000 replications in which
θ1 = 4, θ2 = 0.05 and θ3 = 18
Parameter Mean Mean Empirical Coverage Prob.
Sample Censoring of of (Sample) of
size (n) proportion MLE Asymptotic SE SE 95% CI (in percent)
30 0% 3.634 NA 0.734 NA
0.0458 0.0196 0.0192 87.2
17.695 1.696 1.217 88.7
20% 4.418 NA 0.843 NA
0.0561 0.0212 0.0216 85.1
17.432 1.599 1.412 86.8
50 0% 4.282 NA 0.623 NA
0.0472 0.0183 0.0186 89.1
18.349 1.275 1.114 90.6
20% 3.675 NA 0.747 NA
0.0551 0.0201 0.0203 88.8
17.572 1.214 1.108 89.6
100 0% 3.884 NA 0.575 NA
0.0523 0.0161 0.0151 91.3
18.326 0.996 1.012 92.1
20% 4.211 NA 0.667 NA
0.0533 0.0181 0.0171 90.9
18.426 1.204 1.214 91.4
200 0% 4.003 NA 0.463 NA
0.05083 0.0156 0.0145 92.1
18.231 0.861 0.866 93.6
20% 3.943 NA 0.576 NA
0.0516 0.0162 0.0152 91.5
17.682 0.989 1.003 92.4
reasonably well regardless of the sample size and censoring proportion. The bias of
the mean of MLEs decreases as the sample size increases. The coverage probability
of 95% confidence interval is increasing as the sample size increases. When sample
sizes are 100, 200, the biases are small, the estimated standard errors agree well
with the sample standard errors, and the coverage probabilities are accurate. For all
sample sizes, the biases and coverage probability of CIs are of same magnitudes. The
mean of asymptotic SEs based on Theorem 4 are reasonably close to those empirical
sample SEs based on 1000 Monte Carlo runs. The difference between these two SEs
does not change very much as the sample size changes.
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Table 3.2. Parameter estimates and their inference with 1000 replications in which
θ1 = 3, θ2 = 0.004 and θ3 = 18
Parameter Mean Mean Empirical Coverage Prob.
Sample Censoring Parameter of of (Sample) of
size (n) proportion Name MLE Asymptotic SE SE 95% CI (in percent)
30 0% θ1 2.791 NA 0.771 NA
θ2 0.0171 0.0176 0.0164 98.2
θ3 17.728 1.762 1.749 91.2
20% θ1 3.305 NA 0.878 NA
θ2 0.0179 0.0186 0.0178 98.1
θ3 17.438 1.886 1.857 90.8
50 0% θ1 2.812 NA 0.739 NA
θ2 0.0121 0.0163 0.0153 98.3
θ3 18.079 1.684 1.676 92.2
20% θ1 3.204 NA 0.778 NA
θ2 0.0124 0.0172 0.0159 98.2
θ3 17.887 1.754 1.746 91.8
100 0% θ1 3.149 NA 0.646 NA
θ2 0.0098 0.0151 0.0143 98.6
θ3 17.892 1.592 1.588 93.3
20% θ1 2.845 NA 0.686 NA
θ2 0.0102 0.0161 0.0149 98.5
θ3 18.068 1.666 1.654 93.1
200 0% θ1 2.938 NA 0.589 NA
θ2 0.0083 0.0128 0.0122 99.4
θ3 18.031 1.458 1.445 94.2
20% θ1 3.082 NA 0.0676 NA
θ2 0.0094 0.0145 0.0139 99.1
θ3 18.055 1.565 1.552 93.4
In Table 3.2, the data were simulated under θ1 = 3, θ2 = 0.004 and θ3 = 18. The
mean of MLEs performed reasonably well except for θ2. When true θ2 value was close
to 0 - the boundary of the parameter support, the relative bias of the mean MLE was
much larger than the one when the true value is further away from 0. However, the
coverage probability of 95% confidence interval of θ̂2 is very high compared to the
case when true θ2 is further away from 0 because the relative larger variance when
the true value is close to 0.
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3.5 Estimation and Schedule Finding by Maximum Likelihood Method
3.5.1 Likelihood Function and Estimation in Original Parametric Form
We first consider the estimation procedures for one schedule with multiple ad-
ministrations without censoring. We demonstrate whether the new MLE estimation
procedure for a single administration setting developed in early part of this chapter
can be extended to multiple administration setting.
The likelihood function of θ for given T = {ti, i = 1, ..., n} and schedule s =
{sl, l = 1, ...,m} is
Ln(θ | T , s) =
n∏
i=1
λ(ti|θ, s) exp[−Λ(ti|θ, s)] (3.25)
where θ = (θ1, θ2, θ3). Then, the log likelihood function is in the following form






















h(ti − sl|θ) = θ2
(ti − sl)
θ1
I(0, θ1] + θ2
(θ3 − ti + sl)
θ3 − θ1
I(θ1, θ3] (3.27)
H(ti − sl|θ) = θ2
(ti − sl)2
2θ1
I(0, θ1] + θ2[
θ3
2




where I(0, θ1] is an indicator function of ti − sl in the interval (0, θ1] and I(θ1, θ3] is
an indicator function of θ3 − ti − sl in the interval (θ1, θ3].
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Recall our finding earlier in this chapter that the log likelihood function for θ1
with θ2 and θ3 fixed attains its maximum at one of the order statistics (T1, ...., Tn)
of the observed {ti, i = 1, ..., n} where T1 is the earliest observed time and Tn is the
latest observed time. Specifically,
θ̂1 = Tr̂(θ2,θ3)
where r̂(θ2, θ3) is a function of θ2 and θ3 that can only take the discrete values in [1,
n] and
r̂(θ2, θ3) = arg max
r∈{1,...,n}
{`n(Tr, θ2, θ3)}
In order to extend this result to multiple administration setting, we need to
demonstrate either the first order derivative of the log likelihood function (3.26)
about θ1 is greater than 0 (or less than 0) consistently within each interval [Tr, Tr+1]
(1 ≤ r < n) or the second order derivative of the log likelihood function (3.26)
about θ1 is greater than 0 consistently within each [Tr, Tr+1]. From the log likelihood
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H(ti − sl). (3.34)
We first show ∂
∂θ1
`n(θ) is not consistently greater > 0 (or < 0) in [Tr, Tr+1]. Let
Ai1 = {ti − sl | ti − sl ∈ (0, θ1], l = 1, ...,mi} , Ai2 = {ti − sl | ti − sl ∈ (θ1, θ3], l =
1, ...,mi} and Ai3 = {ti − sl | ti − sl ∈ (θ3,+∞), l = 1, ...,mi}. From definition
of the triangular hazard function h(t|θ), the observed time points in Ai3 do not
contribute to the likelihood function through hazard but do so through cumulative
hazard function. However, the cumulative hazard function of the time points in Ai3
is a function of θ2 and θ3. So they do not contribute to the derivatives of the log
likelihood function about θ1. Substituting the hazard function (3.27), cumulative
hazard function (3.28) and their derivatives into the first order derivative (3.29), we





































(θ3 − ti + sl)2
2(θ3 − θ1)2
}. (3.36)










(θ3−θ1) in the first order derivative is in the denomi-
nator, which complicates the calculation. Even with the constraints as those defined
in Chapter III, the negative part in ∂
∂θ1
Q1(θ1, θ3) makes it possible for the first order
derivative to be less than 0 for some θ1 while greater than 0 for other θ1 in [Tr, Tr−1].
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Similarly, we can show that ∂
2
∂θ21
`n(θ) is not consistently greater than 0 in [Tr, Tr+1].
In addition to the existing observed time points, we also have the shifted time points
{ti − sl, l = 1, ...,mi; i = 1, 2, ..., n}. For estimation purposes, all the observed time
points and shifted time points are incorporated into the likelihood function. How-
ever, we can not prove that the MLE of θ1 can be any one of the observed time
points or shifted time points under the identifiability constraints T1 < θ1 < Tn < θ3.
Therefore, the findings in early part of this chapter can not be directly extended to
the setting of multiple administrations. In next section, we will explore the option of
reparameterizing the original triangular hazard model and its application in multiple
schedule setting.
3.5.2 Likelihood Function and Estimation in Reparameterized Form
Since the proposed MLEs for a single administration setting in last section can
not be extended to a multiple schedule setting, we use the original triangular hazard
model proposed by Braun et al. (2005) for estimation procedures in a multiple sched-
ule setting in this section. For easier computing implementation, we reparameterize
the triangular hazard function as
h(t | β) =

β1t ; 0 ≤ t ≤ β2θ3β1+β2 , β1 > 0
β2(θ3 − t) ; β2θ3β1+β2 < t ≤ θ3, β2 > 0,
0 ; t > θ3, or t < 0.
(3.37)
in which β = (β1, β2, θ3). We can also write the hazard function as h0(t | β) =
β1tI(0,θ1] + β2(θ3 − t)I(θ1,θ3], in which I(a,b] is the indicator that t lies in the interval
(a, b]. By setting the intersection of the two lines in the new hazard function (3.37)
as the change point in the old hazard function (3.1), we can express θ1 and θ2 in
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The new hazard function not only has a simpler mathematical structure but also leads
to a nice interpretation for the change point. The change point can be considered
as a proportion of the total duration of hazard. This proportion is expressed as
the second slope over the sum of the two slopes (we have defined the slopes as
positive values only in the new hazard function). If the hazard goes up quickly and
decreases slowly, then the change point should be closer to 0 than θ3. Otherwise,
if the hazard goes up slowly and decreases quickly, then the change point should
be closer to θ3 than 0. When we discuss the prior information for the change-point
with medical investigators, we can consider the change-point as the proportion of
total duration. Through this proportion, we can derive the relationship between the
two slopes of the triangular hazards. Note that we do not use the reparameterized
hazard form in Bayesian estimation procedures. They are only used in maximum
likelihood estimation procedures. We do not use the normalized CDF and PDF in
reparameterized form either.
Then the new cumulative hazard function (CHF) for Ti is
H(t | β) =





2 ; 0 ≤ t ≤ β2θ3
β1+β2





β2(θ3 − t)2 ; β2θ3β1+β2 < t ≤ θ3,
β1β2θ23
2(β1+β2)
; t > θ3
For the multiple administration setting, the likelihood function (3.25) and log likeli-
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hood function (3.26) still hold with the modifications to h(ti − sl) and H(ti − sl) as
follows
h(ti − sl|β) (3.40)
= β1(ti − sl)I(0,
β2θ3
β1 + β2






















Therefore, we can estimate (β1, β2, θ3) using maximum likelihood with (3.38) and
(3.39) as constraints. So the MLEs of (β1, β2, θ3) are constrained MLEs in the repa-
rameterized form.
Following the notation in subsection 3.5, we extend the likelihood function to
include censored observations. Let (tik, cik) denote the ith observations in schedule
s(k) and nk denote the number of observations in schedule s
(k). Then the likelihood
function is








where β = (β1, β2, θ3), T = {tik, i = 1, ..., nk, k = 1, ..., K}, C = {cik, i = 1, ..., nk, k =














where h(tik − sl)) and H(tik − sl)) are defined in (3.40) and (3.41). The maximum
likelihood method can be used to estimate the unknown parameters β = (β1, β2, θ3)
with constraints (3.38) and (3.39).
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3.6 Estimation and Schedule Finding by Bayesian Approach
The basic structure is described in Braun et al. (2005), where the detailed method-
ology and algorithm can be found. We summarize the main ideas here before pro-
ceeding to simulation studies. Note that we use the original parameterization i.e. θ
proposed by Braun et al. (2005) in the Bayesian estimation procedure.
Let D denote the data available at evaluation time tcur, then the likelihood func-
tion is (3.42), denoting the prior by p(θ), the posterior of θ is
g(θ|D) = Ln(θ | T ,C)p(θ)∫
Ln(θ | T ,C)p(θ)dθ
(3.44)
Because the integral in the posterior can not be obtained analytically under our
assumed model, the posterior quantities are computed via Markov chain Monte
Carlo (MCMC) methods. Specifically, a Metropolis-Hastings algorithm (Robert and
Casella, 1999; Gelman et al., 2004) is used. We experiment with different starting
values and are convinced that the chains converge and cover the entire posterior dis-
tribution using multiple sequences and plots. We eliminate a total of 1000 iterations
as burn-in and then generate additional 3000 samples for summarization.
The priors (θ) are chosen in the form of p3(θ3)p1(θ1|θ3)p2(θ2) because θ1 < θ3.
Both p3(θ3) and p1(θ1|θ3) follow generalized Beta distribution. p2(θ2) follows Gamma
distribution. Tuning parameters k1, k2 and k3 are specified to calibrate the prior
distribution so that the data dominate the posterior distribution. The same notations
are used as those in Braun et al. (2005). For prior elicitation, refer Braun et al. (2005)
for detailed description.
In the following section, we investigated the finite sample behavior of the con-
strained MLEs for the parameters of interest in the reparameterized triangular haz-
ard model and the performance of the proposed model in MTS finding via simulation
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studies. We also implement the simulation study designed in Braun et al. (2005) with
treatment schedule reassignment. The purpose of these simulation studies is to com-
pare the results by maximum likelihood method to those by Bayesian approach. All
results are produced in SAS.
3.7 Application to KGF trial
In order to compare the performance of the triangular hazard model using max-
imum likelihood method and Bayesian approach, we use the same true parameter
values for both methods. Note that β1 and β2 were only estimated directly by max-
imum likelihood method while θ1 and θ2 were only estimated directly by Bayesian
approach. θ3 was directly estimated by both MLE and Bayesian procedures.
We note that θ2 true values were very small (< 0.001) in the simulation study
of Braun et al. (2005). From the numerical studies in early part of this chapter,
the maximum likelihood method had trouble in estimating θ2 when the true values
are less than 0.004 because these small values are too close to the boundary of the
support 0. When the true parameter values are very close to the boundary of the
parameter space, the MLEs are not stable. It may induce larger bias (Hall and Wang,
1999). Therefore, we rescale the time such that 1 unit time in Braun et al. (2005) as
0.1 unit time in our simulation studies. For example, in Braun et al. (2005), θ3 = 18
and θ1 = 3. We set θ3 = 1.8 and θ1 = 0.3 so that we can have θ2 value reasonably far
away from 0 (the boundary of the support for θ2). Then we can derive reasonable
estimate of θ2 using maximum likelihood method and keep the threshold for the
probability of toxicity in our simulation study to be the same as that in Braun et al.
(2005). As a result, reasonable comparisons of the two estimation methods can be
carried out in the simulation result section. Based on equations (3.38) and (3.39),
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we derive the true βi, i = 1, 2 values for simulation. The true parameter values are
shown in Table 3.3, which also contains the actual day 100 (ω = 10 in simulations)
probability of toxicity for each schedule under all scenarios. For trial implementation,
refer to Section 2.4 for details and safety concerns.
Table 3.3. True parameter values of the triangular hazard model for simulation studies
where θ1 = 0.3 and θ3 = 1.8
True Toxicity Prob of Schedule Threshold Prob
Scenario θ2 β1 β2 1 2 3 4 5 6 of Toxicity
1 0.08 0.27 0.06 0.20 0.36 0.48 0.59 0.67 0.74 0.2
2 0.04 0.14 0.03 0.11 0.20 0.28 0.36 0.43 0.49 0.2
3 0.03 0.09 0.02 0.07 0.14 0.20 0.26 0.31 0.36 0.2
4 0.05 0.16 0.03 0.12 0.23 0.32 0.40 0.47 0.54 0.4
5 0.04 0.13 0.03 0.10 0.18 0.26 0.33 0.40 0.46 0.4
6 0.03 0.11 0.02 0.08 0.16 0.23 0.29 0.35 0.40 0.4
7 0.05 0.18 0.04 0.13 0.25 0.35 0.43 0.51 0.58 0.3
8 0.04 0.14 0.03 0.11 0.20 0.28 0.36 0.43 0.49 0.3
9 na na na 0.07 0.14 0.20 0.26 0.31 0.36 0.2
Recall the motivating example in Chapter II in which the investigators wished to
study K = 6 schedules corresponding to 2, 4, 6, 8, 10 and 12 weeks of therapy. We
considered 6 therapy schedules in our simulation studies, s(1), ..., s(6), in which s(k)
did not have natural units and s(k) = {slk, l = 1, ...,mk} for k = 1, ..., 6.
We studied the design with a maximum sample size of 30 patients, which is feasible
in Phase I trials but also sufficient to determine the MTS with reasonable accuracy
demonstrated in our simulations. In each simulation, the subject interarrival times
were assumed to be uniformly distributed from 12 to 16 days.
We examined the design’s performance in nine scenarios using the criterion spec-
ified in section 2.4. In the first six scenarios, schedule s(j) was true optimal schedule
under the jth scenario for j = 1, ..., 6. In scenario 7, the true MTS was located be-
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tween schedule 2 and 3, while in scenario 8, the target schedule (MTS) lay between
schedule 3 and 4 but closer to schedule 3.
Furthermore, we examined the design’s performance under the setting where the
model was misspecified in scenario 9, where schedule 3 was the true MTS, but the
data was not simulated from the triangular hazard model. Instead, we assumed the
toxicity occurred uniformly over the interval [10+14(j−1), 10+14j] under schedule
s(j). In all other scenarios, the actual times to toxicity were simulated assuming the
triangular hazard model with the true parameter values shown in Table 3.3.
Regarding the prior selection in the Bayesian estimation procedures, we used the
investigator belief as a priori to determine the hyperparameters. In our application,
the hazard of toxicity for a single administration vanished after an average of 1.8 unit
time and with a range of 0.4 to 10. The upper bound for θ1 was 0.4. By the methods
described in Braun et al. (2005), the hyperparameters for prior distributions p(θ3)
and p(θ1|θ3) were derived in the computer programs. The investigators also believed
that 12 weeks of KGF would not cause more toxicity, which led us to use the true
parameter value 0.03 of θ2 in scenario 6 of Table 3.1 as the mean of prior distribution
p(θ2).
3.7.1 Study Result and Conclusion
Tables 3.4, 3.5 and 3.6 display the simulation results for triangular hazard model.
Table 3.4 displays the estimated parameter values and corresponding standard errors
for all scenarios. Note that β1 and β2 were only estimated directly using maximum
likelihood method then θ1 and θ2 were derived from β1 and β2 on the MLE row in Ta-
ble 3.4. In contrast, θ1 and θ2 were only estimated directly using Bayesian approach
then β1 and β2 were derived from θ1 and θ2 on the Bayesian row in Table 3.4. θ3
was directly estimated using both maximum likelihood and Bayesian methods. The
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Table 3.4. Estimated parameter values of the triangular hazard model. Each entry is
the estimated parameter value (standard deviation).
Estimation Estimated Value of
Scenario Method θ1 θ2 θ3 β1 β2
1 MLE 0.44 (0.249) 0.074 (0.054) 1.76 (0.681) 0.265 (0.249) 0.090 (0.086)
Bayesian 0.35 (0.074) 0.089 (0.017) 1.81 (0.368) 0.258 (0.032) 0.061 (0.017)
2 MLE 0.48 (0.276) 0.039 (0.027) 1.84 (0.772) 0.142 (0.143) 0.056 (0.042)
Bayesian 0.26 (0.043) 0.045 (0.011) 1.74 (0.523) 0.179 (0.043) 0.031 (0.009)
3 MLE 0.44 (0.261) 0.029 (0.022) 1.75 (0.778) 0.147 (0.148) 0.047 (0.032)
Bayesian 0.27 (0.057) 0.032 (0.008) 1.78 (0.522) 0.117 (0.044) 0.021 (0.006)
4 MLE 0.35 (0.268) 0.054 (0.026) 1.68 (0.783) 0.261 (0.249) 0.059 (0.039)
Bayesian 0.27 (0.073) 0.055 (0.012) 1.77 (0.521) 0.194 (0.066) 0.033 (0.008)
5 MLE 0.36 (0.254) 0.047 (0.024) 1.63 (0.797) 0.234 (0.244) 0.058 (0.034)
Bayesian 0.27 (0.072) 0.042 (0.010) 1.77 (0.354) 0.159 (0.057) 0.031 (0.007)
6 MLE 0.33 (0.258) 0.037 (0.023) 1.58 (0.792) 0.222 (0.254) 0.042 (0.044)
Bayesian 0.27 (0.072) 0.031 (0.008) 1.77 (0.351) 0.117 (0.035) 0.021 (0.006)
7 MLE 0.36 (0.262) 0.061 (0.026) 1.71 (0.792) 0.284 (0.263) 0.059 (0.043)
Bayesian 0.27 (0.064) 0.059 (0.012) 1.78 (0.374) 0.221 (0.063) 0.042 (0.008)
8 MLE 0.51 (0.259) 0.039 (0.024) 1.85 (0.702) 0.153 (0.148) 0.076 (0.049)
Bayesian 0.26 (0.056) 0.046 (0.011) 1.76 (0.399) 0.205 (0.065) 0.032 (0.007)
9 MLE 0.27 (0.185) 0.048 (0.029) 1.39 (0.721) 0.348 (0.325) 0.085 (0.065)
Bayesian 0.27 (0.057) 0.032 (0.008) 1.78 (0.284) 0.117 (0.025) 0.021 (0.005)
estimates by Bayesian approach are posterior means. Tables 3.5 and 3.6 summarize
the frequency at which each schedule was selected as the MTS. The first row of each
scenario in Tables 3.5 and 3.6 contains the percentages of simulations in which each
schedule is identified as the MTS while the second row of each scenario contains the
mean percentages of subjects assigned to a given schedule among the simulations.
We can see from Table 3.4 that the estimates by the maximum likelihood method
have larger biases in most scenarios and also have larger corresponding standard error
estimates across all scenarios. We suspect this fact is due to the small sample size in
our Phase I trials and informative priors used in the Bayesian approach. However,
the parameter estimates in Table 3.4 are still close to the true parameters values,
which provide confidence for us to interpret the results in Tables 3.5 and 3.6.
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Table 3.5. Performance of the triangular model with 30 patients by Maximum Like-
lihood. Each entry on the 1st row is the percentage of simulations a schedule chosen
as MTS, with the average percentage of patients assigned to a given schedule on 2nd
line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 76.7 14.0 7.3 1.3 0.7 0
68.3 17.2 7.2 4.2 1.8 1.3
2 22.7 42.6 19.6 8.7 5.1 1.3
20.6 38.2 15.4 10.6 9.4 5.8
3 10.1 22.1 41.5 13.2 7.6 5.5
15.7 27.5 33.2 10.8 7.2 5.6
4 2.4 11.1 19.8 34.3 21.2 11.2
5.7 13.9 18.1 32.9 17.9 11.5
5 0.7 5.3 11.2 23.1 38.7 21.0
3.6 10.9 13.2 22.8 30.1 19.4
6 0. 4.7 6.3 10.0 25.3 53.7
4.6 8.1 9.9 11.4 13.4 42.6
7 10.7 35.0 32.2 11.7 7.7 2.7
14.0 33.3 29.7 10.3 8.3 4.4
8 0.0 13.3 36.0 24.7 16.5 8.5
4.8 14.4 29.1 20.4 18.8 12.7
9 14.7 25.5 35.3 15.6 6.9 2.0
13.6 21.1 30.5 17.5 9.0 8.3
By comparing the first row within each scenario in both Tables 3.5 and 3.6, there is
no marked difference between the final recommendations by two estimation methods.
In addition, there is little difference in the final recommendation whether the assumed
model is right or not. However, the Bayesian approach performs consistently better
than the maximum likelihood method in terms of the percentage of identifying the
correct MTS in the simulation trials. More specifically, in scenarios 1-2, the Bayesian
approach has a much higher percentage (over 15% more) of identifying the optimal
schedule 1 or 2 as the MTS than the maximum likelihood method. In scenarios
3-4, the Bayesian approach has a moderately higher percentage (between 3%− 10%
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Table 3.6. Performance of the triangular model with 30 patients by Bayesian Approach.
Each entry on the 1st row is the percentage of simulations a schedule chosen as MTS,
with the average percentage of patients assigned to a given schedule on 2nd line within
each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 94.5 4.5 1.0 0 0 0
83.5 11.2 4.2 1.1 0 0
2 10.8 79.2 9.3 0.7 0 0
15.7 67.1 11.0 5.1 1.1 0
3 0.8 29.2 54.1 13.1 2.8 0
8.7 26.3 43.7 12.9 5.3 3.1
4 0 5.5 34.4 38.2 18.5 3.4
3.3 6.2 31.3 35.7 16.1 8.4
5 0 0 14.6 27.7 43.1 14.6
3.3 3.3 12.5 29.8 36.1 18.2
6 0 0 1.5 14.6 24.6 59.3
3.3 3.3 4.4 14.3 25.4 49.3
7 11.2 38.7 36.6 9.3 4.2 0
15.3 32.7 28.2 13.6 6.8 3.4
8 2.1 18.1 46.7 25.7 6.2 1.2
4.0 25.1 36.6 27.2 5.2 1.9
9 5.1 26.7 43.3 21.8 3.1 0
9.2 29.3 36.5 19.1 5.1 0.8
more) of identifying the optimal schedule as the MTS than the maximum likelihood
method. In scenario 7, the pattern of the results is similar as those in scenarios 2-3.
The results in scenario 8 follows the same pattern as those in scenarios 3-4. But the
results from both schedules 2 and 3 in scenario 7 or schedules 3 and 4 in scenario 8
are very similar by both estimation methods.
To compare the average subject assignment within a trial by both estimation
methods, we look at second row within each scenario in both Tables 3.5 and 3.6.
We find that the highest average percentage of subjects is assigned to the true MTS
by both estimation methods across all scenarios. More specifically, in scenarios 1-2,
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the highest average percentage of subjects assigned to the true MTS is much larger
(over 15%) than the average percentages of subjects assigned to other schedules.
However, in other scenarios, there usually exists at least one schedule whose average
percentage of subjects assigned to the specified schedule is very close to the highest
average percentage of subjects assigned to the true MTS in a given scenario. This
fact is expected since the rates of toxicity between neighboring schedules are closer
as the true optimal schedule becomes longer and it is harder for any model based
algorithms to distinguish the schedules.
To assess the effect of the model misspecification on identifying the MTS, we
compare scenario 3 to scenario 9 within Table 3.5, then within Table 3.6 when the
data are not from the assumed model but from the same misspecified model in two
simulation studies. The performance of the algorithm in scenario 9 is similar to
that in scenario 3 even though scenario 3 has a higher percentage of identifying
the schedule 3 as MTS and has more subjects assigned to schedule 3 during a trial
on average by both estimation methods. This fact is expected since the subject
assignment during a trial is determined by the timing when a subject is having a
toxicity but the final schedule recommendation is determined by the overall rate of
toxicity in a trial.
Table 3.7. Average number of observed toxicities (out of 30 subjects) in the simulated
trials using the triangular hazard model.
Estimation Scenario
Method 1 2 3 4 5 6 7 8 9
MLE 8.98 7.32 6.23 11.69 10.87 9.44 9.77 8.32 6.24
Bayesian 7.29 6.35 5.97 11.58 10.43 9.96 9.71 8.25 5.39
Table 3.7 displays an interesting side note on the average number of observed
toxicities out of the total 30 patients. The numbers were very close for both methods.
79
There was no clear pattern on which method had more observed toxicities across all
scenarios. However, the maximum likelihood method had slightly more toxicities
in all but scenario 6. Note that the scenario 8 had more subjects who experienced
toxicities than scenario 3 but less than scenario 4. This is due to the fact that
scenario 8 had a higher threshold toxicity rate pω = 0.3 than scenario 3 (pω = 0.2)
but lower threshold rate than scenario 4 (pω = 0.4).
Table 3.8. Average number of subjects (out of 30 subjects) had reassignment in the
simulated trials using the triangular hazard model.
Estimation Scenario
Method 1 2 3 4 5 6 7 8 9
MLE 0.78 1.87 4.65 5.23 7.22 8.45 2.86 5.98 5.46
Bayesian 0.69 1.56 4.04 5.13 6.84 8.32 2.28 5.23 4.91
Table 3.8 displays another interesting side note on the average number of subjects
received treatment schedule reassignments out of the total 30 patients. The numbers
were very close by both estimation methods with Bayesian approach having slightly
less numbers across all scenarios. We note that the number of subjects had schedule
reassignments increased as the treatment schedule became longer as is expected. We
also note that the number of subjects received schedule reassignments was larger in
scenario 9 than that in scenario 3. This fact may be due to the reason that more
subjects assigned to longer schedules than MTS in scenario 9 than those in scenario
3.
In this chapter, we used both the maximum likelihood and Bayesian approaches to
estimate the parameters of a triangular hazard model proposed for optimal schedule
finding in multiple treatment schedule setting. We first proposed a new procedure
to derive MLEs for the change-point and boundary parameters. The large sample
properties of the proposed MLEs were also derived. Then we showed these results
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could not be extended to a setting in which multiple administrations are given to
each subjects and the number of the administrations varies among the subjects. To
address this problem, we used the constrained MLEs of reparameterized triangular
hazard function for optimal treatment schedule finding. Via simulation, we demon-
strated both maximum likelihood and Bayesian methods performed well under a
variety of settings, including the setting where the model is misspecified. However,
even in the misspecified prior case, the Bayesian approach had a higher percentage
identifying the correct MTS than the maximum likelihood method.
CHAPTER IV
A Non-mixture Cure Model for Optimal Treatment
Schedule Finding
4.1 Introduction
Despite the advantage of our proposed mixture cure model over the existing trian-
gular hazard model in term of interpreting the cure fraction directly, the mixture cure
model still has its limitations. First, the marginal distribution of the mixture cure
model is a mixture distribution that complicates maximum likelihood estimation.
We introduced a latent variable cure status in the likelihood function and used the
EM algorithm to estimate the parameters of interest. From a computing resource
perspective, this estimation procedure is inefficient compared to the procedure of
maximizing the log-likelihood function directly. Furthermore, we modeled the event
rate as a function of treatment schedule in Chapter II, resulting in a population
hazard function that does not have a proportional hazards (PH) structure, which is
a frequently used feature for most survival models. Even if in the situation where
the PH assumption is not correct, the mixture cure model does not provide a natural
structure for testing the departure from PH assumption.
In this chapter, we propose a non-mixture cure model for optimal treatment sched-
ule finding in early-phase clinical trials using adaptive designs, which overcomes the
limitations just mentioned. We use both maximum likelihood and Bayesian methods
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to estimate the unknown parameters and identifying the optimal treatment sched-
ule. Subject accural, data monitoring and outcome-adaptive decision-making are
done sequentially through the simulation studies as in Chapters II and III.
4.2 Model Specification
We first consider the proposed model in a single administration setting. Using
the same notation as in Chapter II, at evaluation time tcur, the amount of time that
a subject has been observed is denoted by T and the indicator of whether or not
a subject is observed with a toxicity prior to time tcur is denoted by C. Let θ,φ
denote the parameters of interest. Then the survival function for T , also known as
the population survival function, is given by
Sp(t|θ,φ) = exp(−θF (t|φ)), θ > 0 (4.1)
where F (t|φ) is a cumulative distribution function (CDF). Since Sp(∞) = exp(−θ)
> 0, the population survival function Sp(t|θ,φ) is not a proper survival function. The
cure rate is Sp(∞) = exp(−θ), with a corresponding event rate, i.e. the probability
of toxicity is 1 − exp(−θ). Furthermore, the population density function is given
by
fp(t|θ,φ) = θf(t|φ) exp(−θF (t|φ))
where f(t|φ) is the probability density function (PDF) corresponding to F (t|φ).
Therefore, the corresponding population hazard function is given by
hp(t|θ,φ) = θf(t|φ),
and the non-mixture cure model yields a multiplicative hazard function in θ and
f(t|φ). This population hazard function has the PH structure if covariate effects
are modeled through θ. But the population hazard function derived from a mixture
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cure model will not have the PH structure even if the covariate effect is modeled
through cure fraction. Furthermore, the PH property in the non-mixture cure model
is computationally attractive as both maximum likelihood and Bayesian approaches
are relatively easy to implement. In addition, even if the PH assumption is not
correct, the non-mixture cure model provides a natural structure for testing the
departure from PH assumption.
In the multiple schedule setting, we assume that k treatment schedules, s(1), ..., s(k),
are investigated in a trial where s(j)=(s1, s2, ..., smj) and that the jth schedule has
a total of mj administrations. Furthermore, s
(j) is nested in s(j+1) for each j =
1, ..., k− 1. We assume that the form of f(.) does not change with successive admin-
istrations. We define the total hazard of toxicity at time t for a subject treated with
schedule s(k) to be





where f(t|φ) was the same as that defined in the single administration setting. We
also put constraints that the total hazard increases as the number of administrations
increases i.e. θk+1/mk+1 ≥ θk/mk. Note that the total hazard is not a sum of hazards
from each administration as was done in the mixture cure model case. We will further
explain the rationale for this approach after we derive the survival function. Then
the cumulative hazard function (CHF) up to t for a subject treated with schedule
s(k) is
Hk(t|φ, θ, s(k)) = θk
∑mk
l=1 F (t− sl|φ)
mk
,
where F (.) is defined as in the single administration setting. Therefore the survival
function up to t for a subject treated with schedule s(k) is given by
Sk(t|φ, θ, s(k)) = exp[−θk
∑mk




We now explain why the CHF Hk(.) is modeled as the average of the CHF from each
administration instead of a sum. In order for Sk(∞) = exp(−θk) to be the cure rate of
treatment schedule k when t approaches ∞, the CHF Hk(t) must approach θk. Since
F (t) is chosen as a CDF and approaches 1 as t approaches ∞,
∑mk
l=1 F (t − sl)/mk
approaches 1 as t approaches ∞ and the CHF Hk(t) approaches θk as t approaches
∞.
In our application, we specify a parametric form for F (.) where
F (t|α, γ) = 1− exp[−tα exp(γ)] (4.2)
follows a Weibull distribution with α ≥ 2 so that the population hazard function
hp(.) has the required non-monotonic pattern that increases to a peak then decreases.
Therefore, the hazard of toxicity attributed to a single administration is modeled by
a Weibull pdf. (See Figure 4.1)
As we discussed in the early part of this section, modeling covariate effects through
θk would allow the population hazard function to have a PH structure. In our ap-
plication, treatment schedule is the only covariate to consider. We chose to adopt
a linear regression model for log-transformed θk i.e. log(θk) = β0 + β1k for simplic-
ity. Since the multiple schedules we investigated are nested, mk = m1k. Then
θk/mk = (exp(β0)/m1)(exp(β1)
k/k) is a non-decreasing function of k when β1 > 0.
Therefore, the constraint θk+1/mk+1 ≥ θk/mk mentioned earlier is satisfied. Thus,
the probability of toxicity at time t is given by
Gk(t|φ, θ, s) = 1 − exp[− exp(β0 + β1k)
∑mk
l=1 F (t− sl|φ)
mk
]
and the probability of toxicity increases as the treatment schedules become longer.
Using the same notation as in Chapter II, we represent the observed data by
Dik = (tik, cik) for the observed time and censoring indicator of the ith sub-
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ject assigned to schedule s(k), respectively, i = 1, ..., nk, where nk is the number
of subjects assigned to schedule s(k). Then the likelihood function of the parameters
β = (β0, β1), φ = (α, γ) can be written as
















exp[− exp(β0 + β1k)
∑mk




where D = {Dik, i = 1, ..., nk; k = 1, ..., K}. Then the log likelihood is given by


























l=1 F (t− sl|φ)
mk
].
4.3 Estimation and Schedule Finding by Maximum Likelihood Method
Consider maximization of the log-likelihood function `(β,φ | D) in (4.4) with
respect to the distribution parameters φ and regression coefficients β. Since the
Weibull family of distributions F (t|φ) satisfy the regularity conditions for MLEs to
exist, the first derivatives about the parameters for gradient vector and the second
derivatives about the parameters for Hessian matrix can be derived from the log-
likelihood function directly. Thus Newton-Raphson method can be used to estimate
the parameters. For our implementation, we have used SAS built-in non-linear opti-
mization procedures called NLPTR which performs well for small- to medium-sized
problems and allows users to specify the linear constraints (include the boundary
constraints) on parameters of interest. The estimation of the probability of toxicity
and identification of the optimal treatment schedule at each evaluation are defined
in Section 2.4.
4.4 Estimation and Schedule Finding by Bayesian Approach
Our schedule-finding algorithm based on a Bayesian approach begins with inde-
pendent informative priors for β and φ. The informative priors may be obtained
either based on historical data from previous single administration studies or by
elicitation from investigators. Since the posterior distributions can not be solved
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analytically under the assumed model, we compute the posterior quantities using
Markov chain Monte Carlo (MCMC) methods. Specifically, a Metropolis-Hastings
algorithm (Robert and Casella, 1999; Gelman et al., 2004) is used. We experiment
with different starting values and are convinced that the chains converge and cover
the entire posterior distribution using multiple sequences and plots. We eliminate
a total of 1000 iterations as burn-in and then generate additional 3000 samples for
summarization.
4.4.1 Priors Based on Historical Data
If dose-toxicity data for a single administration are available from previous studies,
then these data may be used to obtain the priors on φ in the multiple schedule trials.
Denote the time of ith subject in the historical trial by thi and the toxicity indicator
of this subject by chi and all historical data by Dh = {(thi, chi), i = 1, 2, ...nh}, where
nh is the number of subjects in the historical trial. Then the likelihood function of
the available historical data is











where θ is the cure fraction parameter attributed to one administration and is not
the function of the β in multiple administration setting. Assume a vague prior on
all parameters of interest before the historical data are observed, then the posterior
of φ, θ given the historical data is then fpo(φ, θ | Dh) ∝ Lh(φ, θ | Dh) and the prior
used at the start of the schedule-finding trial is fpo(φ, θ | Dh). The informative priors
based on historical data in cure model setting have been studied extensively by Chen
et al. (1999). We refer readers to their work for more details.
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An alternative way of using the available historical data to define priors is to esti-
mate the parameters of interest by either Bayesian approach or maximum likelihood
method. Refer to subsection 2.5.1 for details. Let µ̂. and σ̂
2
. denote the respective
mean and variance of the prior distribution for a parameter of interest derived from
the historical data where ′.′ represents each of parameters α, γ, β0, and β1.
We then select specific functional forms for the prior distributions. Because α > 2,
we assume α − 2 has a gamma distribution with parameters (c1, d1) such that α
has mean c1/d1 and variance c1/d
2
1. Given the prior mean and variance of α that





c1 = (µ̂α − 2)2/σ̂2α and d1 = (µ̂α − 2)/σ̂2α. Since γ may be any real number, we
assume γ follows a normal distribution with hyperparameters (µγ, σγ) where we set
µγ equal to parameter estimate and σγ equal to the standard deviation of parameter
estimate from historical data.
Furthermore, if dose-toxicity data for a single course consisting of multiple ad-
ministrations are also available from previous studies, then these data can be used
to obtain the priors on β in addition to the α, γ in the multiple schedule trials. Fol-
lowing similar arguments as above, we assume β0 follows a normal distribution with
mean equal to µ̂β0 and variance equal to σ̂
2
β0
that are the estimates based on the his-
torical data. Since β1 > 0, we assume β1 has a gamma distribution with parameters
(c2, d2) such that β1 has mean c2/d2 and variance c2/d
2
2. Given the prior mean and






then find c2 = (µ̂β1)




When the individual subject data from trials of the single administration are
available but no data available for a single course, the source for the informative
priors on the parameters of interest can be a mixture of historical data and elicitation
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from the investigators. For example, in our assumed model, the priors for α, γ may
be from historical data while the priors on βi, i = 0, 1 are elicited from investigators.
4.4.2 Elicited Priors
When individual subject data from trials of the single administration or a single
course are not available, informative priors must be elicited from investigators. This
may be done in various ways, with the particular elicitation method tailored to
the clinical setting and investigators’ level of technical expertise. We employed the
following method in our simulation trials.
When no historical data are available, we consider the specific forms of the prior
distributions with slightly different hyperparameterization from the case when his-
torical data are available. We assume α − 2 has a Gamma distribution with mean
µα and variance µαδα, as we need α ≥ 2 to create our non-monotonic hazard. We
assume the remaining parameters each have a similar prior distribution as that in
subsection 4.4.1.
With regard to the cure fraction parameters β, we ask the investigators to specify
an a priori value, Pk, for the cumulative probability of toxicity for schedule k, k =
1, 2, . . . , K. Based upon the simple linear regression model E{log[− log(1− Pk)]} =
b0 + b1k, we use ordinary least squares to find estimates of b0 and b1; we let µβ0 equal
the estimate of b0 and µβ1 equal the larger of 0.01 and the estimate of b1.
With regard to the hazard shape parameters φ, we ask the investigators to spec-
ify an a priori value for the limiting cumulative probability of toxicity for a single
administration. We denote this value Q0 and note that Q0 must be less than the
value of P1 elicited earlier. We also ask investigators to select two time points t1 and
t2 and supply a priori values Q1 and Q2 for the cumulative probabilities of toxicity
at t1 and t2, respectively, for a single administration. Based upon Equation (4.1),
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we first derive the value θ∗ = − log(1 − Q0). Plugging θ∗ and Equation (4.2) into
Equation (4.1), some algebra gives us two equations in terms of two parameters a
and g:
log{− log[1 + log(1−Q1)/θ∗]} = a log(t1) + g
log{− log[1 + log(1−Q2)/θ∗]} = a log(t2) + g
If we let â and ĝ denote the respective solutions to a and g in the above equations,
we set µα = max{2.01, â} and µγ = ĝ.
4.4.3 Calibrating the Prior Distributions of Parameters of Interest
We emphasize that sufficient attention must be given to selection of the variance
hyperparameter values, as they cannot be made arbitrarily large, as is often done
with Bayesian analysis of large data sets. In our research setting, very few data are
available, especially at the beginning of a trial. If the prior distribution is spread over
too broad range, the algorithm will run poorly, severely hindering our algorithm’s
ability to identify optimal schedules during a trial. Therefore, sensitivity analysis of
priors on parameters of interest is essential in order for the data to dominate the prior
distribution in adaptive early-phase clinical trials. As a result, those initially esti-
mated hyperparameters still need fine tuning for priors to work in conjunction with
the data to allow the schedule-finding algorithm provide a safe and reliable design.
However, the calibration methods are different depending on how the informative
priors are derived.
When historical data are available, the following calibration methods are used.
Recall the prior on α follows a gamma distribution with parameters (c1, d1). We set
c1 = aĉ1 and d1 = ad̂1 where ĉ1 and d̂1 are the initial estimates of (c1, d1) derived from
the historical data. The tuning constant a scales the values of (c1, d1) and modulates
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the variability of f(α). In addition, the prior on γ follows a normal distribution
N(µγ, σγ). We set µγ = µ̂γ, σγ = bσ̂γ where µ̂γ and σ̂γ are the initial estimates of
(µγ, σγ) based on historical data. b is the tuning constant in the sensitivity analysis
of priors on γ. Similarly, the prior on β0 follows a normal distribution N(µβ0 , σβ0)
where we set µβ0 = β̂0, σβ0 = dσ̂(β0) and d is a tuning constant used to modulate
the variances of β0 in the sensitivity analysis of the prior on β0. Since the prior on β1
follows a gamma distribution with parameters (c2, d2). We set c2 = eĉ2 and d2 = ed̂2
where ĉ2 and d̂2 are the initial estimates of (c2, d2) derived from the historical data.
The tuning constant e scales the values of (c2, d2) and modulates the variability of
f(β1). By simulating the toxicity times of a small number of subjects, we can compare
the prior means for φ and β to their respective posterior values and evaluate the
effects of a small amount of data on priors.
When no historical data available, we adopt the following calibration methods.
Our approach is to set δα = 1.0 and σ∗ = 0.10µ∗, where the asterisk represents each
of parameters of interest, γ, β0, and β1. Through trial-and-error with several small
simulation studies, we modulate the variances until we find suitable values. For
example, by simulating the first five subjects to experience toxicity on the shortest
schedule, we can compare the posterior means for φ and β to their respective prior
means to determine values of the variances that allow the data to overcome the prior.
Another consideration of the influence of the priors is to examine the resulting
value of F (ω|φ, s(j)) for each schedule s(j) to determine whether the prior may pro-
duce pathological behavior by placing too much of the probability mass of F (ω|φ, s(j))
near 0 or 1 because the consequent distribution of F (ω|φ, s(j)) determine which sched-
ule to be identified as MTS.
We also used misspecified priors such that the prior means are different from the
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true parameters of interest. The simulation results changed slightly, but overall, the
final conclusions were relatively unchanged. Thus the proposed model is insensitive
to the misspecified priors and different starting values as long as the priors are
informative at the beginning of a trial but do not dominate the data at later points
in the trial.
4.5 Application to KGF trial
In this section, we investigate the performance of the proposed non-mixture
cure model in optimal treatment schedule finding via simulation studies using both
Bayesian and maximum likelihood approaches. All results are produced in SAS.
The KGF trial is described in the motivating example of Chapter II. In this
section, we implement this trial using our proposed non-mixture cure model under
different study set up scenarios. In order to compare the performance of the maxi-
mum likelihood and the Bayesian approaches, we use the same true parameter values
for both methods. To be consistent with the simulation set up for other proposed
models in previous chapters, we rescale the time such that 1 unit time in Braun
et al. (2005) as 0.1 unit time in our simulation studies. Then, we can compare the
performance of different proposed models by the same estimation method in scenario
9. The true parameter values are shown in Table 4.1, which also contains the actual
day 100 (ω = 10 in simulations) probability of toxicity for each schedule under all
scenarios.
To be consistent with application set up in the previous chapters, we use very
similar study settings in this section. We summarize the main ideas as follows. We
consider 6 therapy schedules in our simulation studies, s(1), ..., s(6), in which s(k) do
not have natural units and s(k) = {slk, l = 1, ...,mk} for k = 1, ..., 6. We study the
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Table 4.1. True parameter values of the non-mixture cure model for simulation studies
True Toxicity Prob of Schedule Threshold Prob
Scenario α γ β0 β1 1 2 3 4 5 6 of Toxicity
1 3 0 -1.97 0.47 0.20 0.30 0.43 0.60 0.77 0.90 0.2
2 3 0 -2.27 0.39 0.14 0.20 0.28 0.38 0.51 0.65 0.2
3 3 0 -2.40 0.30 0.11 0.15 0.20 0.26 0.33 0.42 0.2
4 3 0 -2.11 0.36 0.16 0.22 0.30 0.40 0.52 0.65 0.4
5 3 0 -2.47 0.36 0.11 0.16 0.22 0.30 0.40 0.52 0.4
6 3 0 -2.82 0.36 0.08 0.11 0.16 0.22 0.30 0.40 0.4
7 3 0 -2.27 0.49 0.15 0.24 0.36 0.52 0.69 0.85 0.3
8 3 0 -3.26 0.69 0.07 0.14 0.26 0.45 0.69 0.90 0.3
9 na na -2.40 0.30 0.11 0.15 0.20 0.26 0.33 0.42 0.2
design with a maximum sample size of 30 patients. In each simulation, the subject
interarrival times are assumed to be uniformly distributed from 12 to 16 days.
We examine the design’s performance in nine scenarios using the criterion specified
in Section 2.4. In the first six scenarios, schedule s(j) is optimal under the jth
scenario for j = 1, ..., 6. In scenario 7, the true MTS is located midway between
schedule 2 and 3, while in scenario 8, the target schedule (MTS) lay between schedule
3 and 4 but much closer to schedule 3. In scenario 9, we examine the design’s
performance under model misspecification, where schedule 3 is the true MTS, but
the data is not simulated from the assumed non-mixture cure model with Weibull
distribution. Instead, we model the toxicity to occur uniformly over the interval
[10 + 14(j − 1), 10 + 14j] under schedule s(j). Except in scenario 9, the actual times
to toxicity are simulated assuming the parameter values shown in Table 4.1 under
the non-mixture cure model with Weibull distribution of parameter values α = 3 and
γ = 0;
When using a Bayesian approach, All the priors are informative, which mean their
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variations are relatively small compared to the conventional priors for the studies with
large sample size. With regard to the prior distributions for φ and β, we use the
elicited values from the investigators as in Table 4.1. For example, the investigators
supply the values P1 = 0.08, P2 = 0.11, P3 = 0.16, P4 = 0.22, P5 = 0.30, P6 = 0.40,
corresponding to the scenario 6 in Table 4.1. Thus, they believe the longest schedule,
s(6), is optimal, a belief that leads to a misspecified prior for the first five scenarios.
Similarly, we can use any other row of probabilities of toxicity to specify the priors
for the β as long as the row we choose is the investigators’ belief. The investigators
also believe that one administration has a limiting cumulative probability Q0 = P1/6
(one-sixth of the shortest schedule), with corresponding cumulative probabilities of
toxicity Q1 = Q0/4 and Q2 = Q0/2 at times t1 = 6 days and t2 = 9 days, respectively.
From these elicited values, we used the methods described in Section prior elicitation
to estimate the mean hyperparameter values µα = 2.9, µγ = −0.1, µβ0 = −2.9 and
µβ1 = 0.36.
4.5.1 Study Result & Conclusion
Tables 4.2, 4.3 and 4.4 display the simulation results for our current model. Table
4.2 displays the estimated parameter values and corresponding standard deviations
under all scenarios. Tables 4.3 and 4.4 summarize the respective frequency at which
each schedule is chosen as MTS by maximum likelihood and Bayesian approaches.
Within each scenario in Table 4.3 and 4.4, each entry on the first row is the percentage
of simulations in which a given schedule is identified as the MTS while the entry on
the second row is the average percentage of subjects assigned to a given schedule
during a trial.
We can see from Table 4.2 that the biases of parameter estimates by maximum
likelihood are larger than those by Bayesian approach in most scenarios. Further-
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Table 4.2. Estimated parameter values of the non-mixture cure model. Each entry is
the estimated parameter value (standard deviation).
Estimation Estimated Value of
Scenario Method α γ β0 β1
1 MLE 2.97 (1.55) -0.18 (0.25) -2.10 (1.59) 0.53 (0.43)
Bayesian 3.06 (1.13) -0.10 (0.13) -2.00 (1.12) 0.54 (0.27)
2 MLE 3.23 (1.71) -0.19 (0.38) -2.85 (1.86) 0.52 (0.51)
Bayesian 3.31 (1.18) 0.06 (0.21) -2.50 (1.16) 0.44 (0.22)
3 MLE 3.47 (1.73) 0.15 (0.35) -2.93 (2.15) 0.46 (0.46)
Bayesian 3.28 (1.22) -0.07 (0.19) -2.53 (1.18) 0.37 (0.29)
4 MLE 3.14(1.88) -0.19 (0.28) -2.67 (2.05) 0.51 (0.57)
Bayesian 3.22 (1.26) 0.07 (0.23) -2.22 (1.19) 0.41 (0.25)
5 MLE 3.26 (1.81) 0.17 (0.37) -3.00 (2.49) 0.51 (0.60)
Bayesian 3.11 (1.23) 0.09 (0.23) -2.57 (1.34) 0.43 (0.23)
6 MLE 3.41 (1.45) -0.17 (0.38) -3.22 (3.03) 0.48 (0.59)
Bayesian 3.27 (1.15) -0.11 (0.27) -2.98 (1.27) 0.44 (0.34)
7 MLE 2.81 (2.18) -0.15 (0.47) -2.80 (2.10) 0.61 (0.62)
Bayesian 3.13 (1.77) 0.13 (0.31) -2.35 (1.28) 0.56 (0.38)
8 MLE 2.92 (2.72) 0.17 (0.49) -3.65 (2.09) 0.81 (0.89)
Bayesian 3.15 (1.43) -0.07 (0.33) -3.39 (1.60) 0.72 (0.65)
more, the standard errors by maximum likelihood are consistently greater than those
by Bayesian approach among all scenarios. Those facts may be due to the small
sample size in our simulation studies and informative priors used in our Bayesian
procedures. Despite the above facts, the parameter estimates are very close to the
true values provide confidence for us to interpret the results in Tables 4.3 and 4.4.
After a direct comparison of the two estimation methods ( first line in Table 4.3 vs
first line in Table 4.4 within each scenario), we find that Bayesian approach perform
consistently better than maximum likelihood method when the priors chosen in the
Bayesian procedures are informative at the beginning of a trial but do not dominate
the data at later points in a study. However, both methods lead to similar conclusions
as far as the final recommendation for the optimal schedule. Specifically, in scenarios
1 & 2, the Bayesian approach has a much higher percentage (over 15% more) of
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Table 4.3. Performance of the non-mixture cure model with 30 patients by maximum
likelihood method. Each entry on the 1st row is the percentage of simulations a schedule
chosen as MTS, with the average percentage of patients assigned to a given schedule
on 2nd line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 72.2 25.6 1.8 0.4 0 0
63.3 23.3 7.2 4.1 2.1 0
2 21.8 46.3 19.7 8.7 5.3 1.2
28.4 36.2 17.2 9.2 6.4 2.6
3 9.7 23.9 42.9 13.4 6.2 4.8
11.9 23.4 35.8 15.4 8.8 4.6
4 5.2 8.8 22.7 41.1 16.4 5.9
6.8 14.1 19.1 37.2 14.3 8.4
5 2.6 7.4 10.4 19.9 40.2 19.5
3.6 8.1 12.2 21.8 33.2 21.2
6 2.9 4.1 6.7 11.4 21.7 53.2
3.3 5.6 7.4 18.6 25.6 39.5
7 13.7 42.1 39.1 4.7 0.4 0
17.1 34.4 32.1 9.5 4.3 2.6
8 3.7 15.5 44.3 26.1 9.4 1.0
3.5 23.6 36.1 25.1 8.7 3.0
9 16.1 22.2 37.4 17.3 5.0 2.0
16.2 17.9 32.9 16.7 10.2 6.1
identifying the true optimal schedule as the MTS than the maximum likelihood. For
example, Bayesian approach has about 91% and 69% of identifying schedule 1 and
2 as the MTS while the maximum likelihood has about 72% and 46% in scenario
1 and 2, respectively. We suspect this fact is due to the following reasons. First,
we start a trial at the lowest schedule and only allow incremental escalation during
a trial. Second, Bayesian estimation approach produces much smaller variations of
parameter estimates than maximum likelihood estimation method. Therefore, it is
easier for Bayesian method to distinguish schedule 1 or 2 as MTS than maximum
likelihood in scenarios 1 and 2 (when the schedule 1 or 2 is the true optimal schedule).
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Table 4.4. Performance of the non-mixture cure model with 30 patients by Bayesian
approach. Each entry on the 1st row is the percentage of simulations a schedule chosen
as MTS, with the average percentage of patients assigned to a given schedule on 2nd
line within each scenario.
Schedule (number of weeks)
Scenario 1 (2) 2 (4) 3 (6) 4 (8) 5 (10) 6 (12)
1 91.3 8.7 0 0 0 0
77.2 22.6 0.2 0.1 0 0
2 14.9 68.8 15.6 0.7 0. 0
15.9 51.4 18.2 11.9 3.6 0
3 4.4 17.4 53.1 18.3 6.3 0.5
10.8 22.3 38.7 15.9 9.2 3.1
4 1.2 6.4 29.4 44.1 15.8 3.1
5.1 9.6 23.2 40.3 14.8 7.0
5 0 2.8 5.2 29.8 45.1 17.1
3.4 6.8 11.8 22.1 37.7 18.2
6 0 2.8 4.8 6.9 23.6 61.9
3.3 5.2 9.3 14.3 21.9 46.0
7 9.6 45.7 38.1 6.6 0 0
16.6 37.5 29.2 9.6 5.1 2.1
8 2.4 12.6 45.8 28.6 8.4 2.1
4.6 11.0 39.0 29.6 9.2 6.5
9 4.8 29.2 41.7 20.8 3.5 0
9.8 21.3 35.7 21.9 8.2 3.1
Furthermore, in scenarios 3-6, the Bayesian approach has a moderately higher
percentage (about 5% to 10% more) of identifying the true optimal schedule as the
MTS than the maximum likelihood. In scenario 7, both methods produce very sim-
ilar results because the true MTS is midway between schedules 2 and 3. However,
in scenario 8, the Bayesian approach has a higher percentage of identifying schedule
3 or 4 as the MTS than the maximum likelihood, even though the percentage of
identifying both schedule 3 and 4 as the MTS are very similar for both methods
because the true optimal schedule is somewhere closer to schedule 3 than to schedule
4. These results are expected as our algorithm should work well in optimal sched-
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ule finding even when no true treatment schedule exists among the given multiple
schedules, but there only existis a schedule that is close to the true MTS or the true
MTS is between two existing schedules.
We then compare the second line in Table 4.3 to second line in Table 4.4 within
each scenario and find that the highest average percentage of subjects in each scenario
in a simulation trial is assigned to the true optimal schedule by both estimation
methods. More specifically, under scenario 1, on average, about 63% (the highest
percentage) of subjects is assigned to schedule 1 in a simulation trial using the
maximum likelihood while about 77% (the highest percentage) of subjects is assigned
to schedule 1 using the Bayesian method. Furthermore, under scenarios 5 and 6, the
Bayesian approach achieves the optimal schedule faster than the maximum likelihood
because the up-down-scheme used in the maximum likelihood at the beginning of
a simulation trial slows down the escalation process by grouping when the longer
schedule (schedule 5 or 6) is the true optimal schedule. We also note that more
subjects are assigned to the schedules shorter than true MTS than those schedules
longer than the true MTS. This result indicates that the safety constraints described
in Section 2.4 are implemented fairly well in our simulation studies.
To assess the impact of model misspecification on optimal treatment schedule
finding, we first compare scenario 3 to scenario 9 in Table 4.3, then in Table 4.4.
In general, we find that the ability of our algorithm to correctly identify the MTS
is relatively unaffected by model misspecification using both estimation methods,
although, fewer subjects are assigned to the true MTS when our assumed model
does not reflect actual toxicity times. This result is expected, as schedule assignment
during the study will be impacted by when each subject is having toxicity, while the
final decision of the study is only impacted by the overall rate of toxicity.
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Table 4.5. Average number of observed toxicities (out of 30 subjects) in the simulated
trials using the non-mixture cure model.
Estimation Scenario
Method 1 2 3 4 5 6 7 8 9
MLE 8.85 8.05 6.58 11.22 10.91 9.06 9.93 9.15 6.41
Bayesian 7.94 7.12 6.31 12.09 11.15 9.92 10.11 8.45 5.98
An interesting note is about the average number of observed toxicities out of the
total 30 patients, which is displayed in Table 4.5. Overall, the numbers of observed
toxicities are very similar for both methods with the differences between the two
methods are less than 1 across all scenarios. We also observe that on one hand, the
numbers of observed toxicity are slightly larger in scenarios 1-3 by the maximum
likelihood than those numbers by the Bayesian approach. On the other hand, the
numbers of observed toxicity are smaller in scenarios 4-6 by the maximum likelihood
compared to those numbers by the Bayesian approach. We suspect this fact may be
due to the reason that more subjects are assigned to shorter schedules in scenarios
1-3 while more subjects are assigned to longer schedules in scenarios 4-6 using the
Bayesian approach compared to using the maximum likelihood method.
Furthermore, we note the following pattern: the decreasing mean number of ob-
served toxicities from scenarios 1-3 and from scenarios 4-6 but the average number
of toxicity in scenarios 4-6 are larger than those in scenarios 1-3 using both meth-
ods. These facts are due to the simulation set up. We assume that the threshold of
probability of toxicity is 0.2 for scenarios 1-3 while the threshold is 0.4 for scenarios
4-6. In addition, we find that the numbers in scenario 3 are very similar to those in
scenario 9 by both estimation methods because the probability of toxicity set up in
two scenarios are exactly same even though the data are simulated under different
models.
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Table 4.6. Average number of subjects (out of 30 subjects) had reassignment in the
simulated trials using the non-mixture cure model.
Estimation Scenario
Method 1 2 3 4 5 6 7 8 9
MLE 0.36 1.76 4.36 5.47 6.95 7.24 3.08 4.69 4.57
Bayesian 0.12 1.63 3.37 5.61 7.09 7.58 2.46 4.31 3.54
Another interesting side note is in regard to the average number of subjects out of
30 subjects who received a reassignment to their originally assigned schedule, which
is displayed in Table 4.6. The numbers are very similar using both methods with
the Bayesian method having slightly larger numbers for scenarios 1-3 and having
slightly smaller numbers for scenarios 4-6. Overall, the number of subjects with
treatment reassignment increases as the true optimal treatment schedule becomes
longer, which is expected. Furthermore, we note the numbers in scenario 3 are very
close to those in scenario 9 by both approaches because the probability of toxicity
set up in two scenarios are exactly same and both scenarios have schedule 3 as the
true MTS although the data are simulated from different models. It is nonetheless
interesting to note that the working model affects very weakly on the results.
We have developed a non-mixture cure model with additive hazard to identify
an optimal schedule among a fixed number of nested treatment schedules using both
maximum likelihood and Bayesian approaches. Subject accrual, data monitoring and
outcome adaptive decision-making are done sequentially and continuously through-
out Phase I trials. Via simulation, we have demonstrated the excellent operating
characteristics of our algorithm when the assumed model is correct or misspecified,
as well as when the prior is correctly or incorrectly specified.
CHAPTER V
Summary and Future Research
5.1 Summary
This dissertation extends the optimal treatment schedule finding method proposed
in Braun et al. (2005) by using both maximum likelihood and Bayesian methods, by
proposing more smooth parametric models. More specifically, we have developed
three classes of additive hazard models to identify an optimal schedule among a
fixed number of possible nested treatment schedules. The first class of the proposed
parametric models is the pseudo non-mixture cure model. The triangular hazard
model discussed in Chapter III is an example of this class of models. The second
class of the proposed parametric cure models is the mixture cure model where the
treatment schedule effect is modeled through the cure fraction. The sectional Weibull
hazard model discussed in Chapter II is an application of this class of models. The
third class of the proposed parametric models is the non-mixture cure model. The
Weibull density function (as a hazard) model we discussed in Chapter IV is an illus-
tration of this class of model. We demonstrated the applications of these parametric
models through simulation studies and compared their performance by two different
estimation methods.
There are similarities among the three classes of proposed models. We first com-
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pare the first class of models to the third class. Returning to Equation (4.1), the
survivor function of a single administration, we note that the triangular model of
Braun et al. (2005) can be viewed as a pseudo non-mixture cure model. Both θ1
and θ3 in the triangular model share the roles of our parameters α and γ and relate
most to when toxicity occurs, while θ2 in the triangular model relates most to the
cumulative probability of toxicity like our parameter θ in the non-mixture cure model
which we then generalize to accommodate multiple administrations.
We then compare the second class of models to the third class. There is a distinct
mathematical connection between a mixture cure model and a non-mixture model.
We use the single administration setting to illustrate the mathematical connection.
Suppose that p is the event rate and S(.) is the survival function for subjects experi-
encing toxicity. Then from the population survival function (4.1) in the non-mixture
cure model, we obtain the survival function for those with toxicity as
S(t) = P (T > t|T <∞) = exp(−θF (t))− exp(−θ)
1− exp(−θ)
where p = 1− exp(−θ). Then, we can write Sp(t) = 1− p+ pS(t). Thus Sp(t) is a
mixture cure model with event rate p and survival function S(t) for those subjects
experiencing toxicity. This shows that every non-mixture cure model defined as (4.1)
can be written as a mixture cure model. This result also implies that every mixture
cure model corresponds to some model of the form (4.1) for some θ and F (.). If the
covariate effects are modeled through θ, then the entire population is modeled as a
proportional hazards (PH) model in a non-mixture cure model whereas only those
with toxicity can be modeled with a PH structure in a mixture cure model.
Even though there is a mathematical relationship between the non-mixture cure
model and the mixture cure model, the non-mixture cure model has some distinct
advantages over the mixture cure model from application perspective. As we discuss
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in the previous paragraph, the non-mixture cure model facilitates the PH structure
naturally which is a frequently used property in most clinical trials. For example,
the non-mixture cure model can directly incorporate subject-specific covariates into
regression model for the cure fraction, while still allowing the pattern of toxicity to
remain constant among subjects, i.e. proportional hazards. Even in applications
that the PH assumption may be violated, the non-mixture cure model still provide
a natural structure for testing the departure from the PH assumption. Furthermore,
the non-mixture cure model allows for a broader family of parametric models, such
as the toxicity time patterns beyond the up-and-down (non-monotonic) pattern we
required because parametric models are more attractive in adaptive early-phase clin-
ical trials. Most importantly, the non-mixture cure model offers certain technical
advantages when developing maximum likelihood or Bayesian estimation procedures
because of the usual properties of standard lifetime distributions, i.e. continuity,
infinite support on positive real line, etc. Therefore, we prefer a non-mixture cure
model with Weibull family of distributions in optimal treatment schedule finding.
Via simulation, we demonstrate both maximum likelihood and Bayesian approaches
performed well under broad range of scenarios we investigated, including the case
when the model was misspecified. But with the maximum likelihood method, the es-
timated parameters had a larger variability compared to the results by the Bayesian
approach due to small sample size of early-phase clinical trials. With the Bayesian
approach, we had to use informative priors in our application due to the same rea-
son. As a result, we had to carefully choose a tuning parameter to allow the prior
provide enough information at the beginning of an adaptive early-phase trial but not
dominate the posterior at later point in the given trial.
However, even in the case when the priors were misspecified, the Bayesian ap-
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proach still had a higher percentage of identifying the correct MTS than the max-
imum likelihood method. Therefore, we would prefer a Bayesian approach over a
maximum likelihood method in adaptive early-phase clinical trials because a max-
imum likelihood method requires a two-stage design. Before any toxicity occurs, a
traditional up-down scheme or a Bayesian approach is used to initiate the trial. Once
a toxicity occurs and more than 15 subjects are enrolled in our simulated trials (the
number of the subjects enrolled in a trial at switching point may be different for
different application problems, the 15 is applicable to our application in the KGF
trial), then the trial switches to a maximum likelihood method. With a Bayesian
approach, no such two-stage design is necessary.
Furthermore, comparing the three classes of proposed models via simulation,
Bayesian approaches slightly overestimated the probabilities of toxicity so that more
subjects were assigned to the schedules shorter than the true MTS compare to the
schedules longer than the true MTS in our simulation studies. Overall, a Bayesian
approach performed fairly well for any assumed models in our simulation studies
where the toxicity rates of the treatment schedules were moderate. We also conclude
that what matters are the toxic probabilities of each schedule and not so much the
models generating these probabilities.
5.2 Future Research
Via simulation, we have demonstrated the excellent operating characteristics of
our algorithms no matter whether the assumed models are correct or misspecified.
However, we have not been able to determine which proposed model is optimal
from the perspective of statistical criteria for model selection. Therefore, we plan
to further investigate statistical methods for model selection in multiple treatment
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schedule setting. Since our simulations have demonstrated the Bayesian approaches
constantly performed better than maximum likelihood methods in adaptive early
phase clinical trials, we plan to use Bayesian model selection methods. Berger and
Pericchi (1997) listed many advantages of Bayesian approaches to model selection;
the advantage most relevant to our discussion is that Bayesian model selection does
not require nested models (our three proposed models are not nested) nor standard
distributions and regular asymptotic results (two of our proposed models have a
change point in the hazard function).
Seltman et al. (2001) used Bayes factors and posterior model probabilities for
selecting optimal models in the case of survival models with a cure fraction. Schwarz
(1978) derived the Bayesian Information Criterion (BIC) as a large sample approx-
imation to twice the logarithm of the Bayes factor. Another model selection proce-
dure is based on a cross-validation predictive check (Stone, 1974; Geisser, 1993) and
is called the conditional predictive ordinate (CPO) (Gelfand et al., 1992; Geisser,
1993 and Gelfand, 1995). One attractive feature of the CPO is that it does not
require proper priors. As a result, it has been used extensively in the literature for
model selection. Chen et al. (2002) used for non-mixture cure model selection. Dey
et al. (1995) used for determining the number of components in a mixture distri-
bution. Gelfand (1995) demonstrated good performance of various Bayesian model
determination techniques in investigating nonlinear mixed-effects models on a small
data set. However, little research exists on the small-sample performance of Bayesian
model selection techniques in the area of cure models. Furthermore, Yu (2004) con-
ducted a simulation study to compare the performance of the three Bayesian criteria:
BIC, posterior model probabilities, and the CPO statistic, in model selection of cure
models. Their research demonstrated that the CPO performed reasonably well in
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most settings and much better than both Bayes factors and BIC.
Therefore, we choose CPO as our criterion for model selection. Specifically, we
will calculate the CPO for each observation under the three proposed models and
derive the B* statistic proposed by Gelfand et al. (1992) related to the CPO of each
model. The B* statistic is more useful than the CPO when comparing more than two
models simultaneously; the model with the larger B* statistic is judged the better
fitting model.
Under our model, one could observe only patients who receive the shortest se-
quence, s(1) to make predictions about any s(j), j ≥ 1. We are exploring the possi-
bility of loosening strong homogeneity assumption on the hazard of toxicity at each
administration. For example, we consider develop models that account for inhomo-
geneity across schedules. Back to the motivating example, suppose one course of
treatment is composed of administrations at day 1, day 2 and day 3 then 4 days off,
then another 3 days of administrations. If we assume the hazard of toxicity at day 1
follows a Weibull PDF, then we could model the hazard of toxicity at later adminis-
trations follow the similar Weibull PDF pattern with a different normalization factor
depending on the dose response relationship, which might possibly be determined
from the historical data. If no related historical data were available, we could also
solicit the hazard of toxicity pattern from the investigators in order to determine our
hazard function structure for later administrations.
Braun et al. (2005) have recently updated their algorithm to allow the dose to vary
among administrations by modeling each of their triangular parameters to vary as a
parametric function of dose (Braun et al. (2007)). We plan to make similar updates
to our algorithm by including dose as a covariate in our model for the cure fraction.
Such an approach would assume proportional hazards among doses, although we
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could also allow the parameters α and γ to vary by dose if proportional hazards was
not a reasonable assumption. We can also easily generalize our model to allow for
hazards that change with each administration by modeling the hazard parameters
as a function of administration number.
We could also extend our models to allow for optimal treatment schedule find-
ing with combinations of two agents where both agents have a multiple treatment
schedule. In this scenario, our outcome remains the time to toxicity; however, the
non-mixture cure model would incorporate main effects of both agents into the cure
fraction, as well as a term for any possible interaction between the agents. The more
challenging aspect of this design is how to incorporate both agents into the time to
toxicity hazard, as the two agents will likely differ in both the number of administra-
tions, as well as the times of administration. Nonetheless, once we have a reasonable
model, the Bayesian estimation procedures developed in this dissertation could be
used in this design.
Most importantly, our model can be adopted for any clinical trial in which investi-
gators wish to measure the impact of multiple administrations on a binary outcome.
Thus, our algorithm could be used in a Phase II study seeking to determine how
many administrations are necessary for a desired rate of efficacy, or in a Phase III
study comparing two different schedules or doses of the same agent or two different
agents in a large sample of (randomized) subjects. Furthermore, if our methods were
applied to a large cohort of subjects like that in a Phase III trial, we could model
the single-administration hazard non-parametrically with standard techniques rather
than forcing a parametric model on the event times.
Even though our proposed models have been focused on Phase I trials evaluating
the safety of multiple treatment schedules, we could also extend our methodology
108
to evaluate simultaneously the safety and efficacy of multiple administrations like
that proposed by Thall and Cook (2004) for single administration setting. In this
case, our responses would be bivariate outcomes with a safety outcome as time to
events and an efficacy outcome as categorical or continuous. If the efficacy outcome
is also time to events and a non-mixture cure model is a reasonable assumption in
the application, then our non-mixture cure model could be extended to a bivariate
non-mixture cure model with a shared frailty to account for the correlation between






Proofs for Theorems in This Dissertation
A.1 Proofs for Theorems in Chapter III
Proof of Theorem 1: From the log likelihood function (3.4), we derive the first










































We can see for θ1 ∈ (0, T1], ∂∂θ1 `n(θ) > 0, therefore `n(θ1) is strictly increasing over
(0, T1]. The maximum value of `n(θ1) is attained at T1.
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The first order derivatives of Q1(θ1, θ3) and Q2(θ1, θ3) about θ1 are
∂
∂θ1












In order to have ∂
∂θ1
































< θ1. Therefore, `n(θ1) is decreasing. This
will guarantee that the maximum value of `n(θ1) is attained at Tn when θ1 ∈ [Tn, θ3).







































The first order derivatives of Q1(θ1, θ3) and Q2(θ1, θ3) about θ1 are
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For θ1 ∈ [Tr, Tr+1], if −rθ3+nθ1 ≥ 0, then ∂∂θ1 `n(θ) > 0, so `n(θ1) is strictly increasing




`n(θ) may <= 0 then > 0. Furthermore, the second order derivatives of






























`n(θ) ≥ 0 for all θ1 ∈ [Tr, Tr+1]. So
`n(θ1) is decreasing until reaching minimum, then increasing over [Tr, Tr+1]. There-
fore, the maximum value of `n(θ1) is attained at Tr or Tr+1 when θ1 ∈ [Tr, Tr+1]. The
proof of Theorem 1 is complete.
Proof of Theorem 2: To prove item 1, we first substitute θ̂1 = Tr̂(θ2,θ3) in the
likelihood function, then simplify the equation (3.5) and write it in term of M(θ) as
following
r̂(θ2, θ3) = arg max
r∈{1,...,n}
{M(Tr, θ2, θ3)} (A.8)
Where
















































dominant on both sides of inequality. We know Ti < Tr for i < r. Then, the smaller
the r is, the larger the M(Tr, θ2, θ3) is. Thus, r decreases when θ3 increases.
To prove item 2, let θ3 → +∞, assume θ1 not approach T1, then exists some









(θ3−T1) approach 1 as
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θ3 → +∞. Therefore, for large enough θ3, Ln(Tr, θ3) < Ln(T1, θ3), which contradicts
that Tr(r 6= 1) is the MLE. Thus, r̂(θ2, θ3) = 1.
To prove item 3, if θ3 = Tn, assume θ1 6= Tn, then exists a term θ3−Tn = Tn−Tn =
0 in the likelihood function Ln(θ1, θ3) such that Ln(θ1, θ3) = 0. So θ1 has to be Tn.
Thus, r̂(θ2, θ3) = n.
To prove item 4, we apply the result from Theorem 1 that r̂(θ2, θ3) is a function
of θ2 and θ3 that can only take the discrete values in [1, n]. From item 1 of this
Theorem, r̂(θ2, θ3) is a decreasing function of θ3. Therefore, r̂(θ2, θ3) has (n − 1)
discontinuity points {θ3,r, r = n− 1, n− 2, ..., 1} when r values step down from n to
n− 1, n− 1 to n− 2, ..., from 2 to 1.
To derive θ3,r as defined in (3.7), let r̂(θ2, θ3) = r, then θ̂1 = Tr. So M(Tr, θ2, θ3) ≥
M(Tr−1, θ2, θ3), M(Tr, θ2, θ3) ≥M(Tr+1, θ2, θ3) Thus, θ3,r is the solution of equation
M(Tr, θ2, θ3) = M(Tr+1, θ2, θ3). The other endpoints in equation (3.7) can be derived
in a similar fashion. The proof of Theorem 2 is complete.
Proof of Lemma 1: Let Sθ1 = (θ1−δ, θ1 +δ) where δ stands for δ(θ1, θ1(0)) as in
condition 1. Let Lk(θ1) =
∑k
i=1 log f(ti, θ1). Choose any η, define Ω = [0, θ3]
⋂
[θ1 :
|θ1 − θ1(0)| ≥ η]. Since Ω is compact and
⋃
{Sθ1 : θ1 ∈ Ω} ⊃ Ω, there exists a finite
large number M and a finite set {θ1,1, ..., θ1,M} ⊂ Ω such that
⋃M
i=1 Si ⊃ Ω.
Under condition 1, by law of large numbers, for any ε > 0 there exist integers









{log f(tj, θ1)− log f(tj, θ1(0))} (A.10)






















≤ M ∗ ε/M = ε.
This proves Lemma 1.
Proof of Lemma 2: Let Ui = Xi − θ1, i = 1, ..., n. Then Uis are i.i.d with p.d.f
fu(u) and fu(0) = α > 0. We then apply the result of Lemma 7 in Yao (1986) and
derive the result of Lemma 2.
Proof of Theorem 4: To prove the consistency of the MLEs, we will show
CDF F (t|θ) and pdf f(t|θ) satisfy required conditions. First, it can be proved that
i) f(t|θ) is a uniformly continuous density which vanishes on (−∞, 0) and (θ3,+∞)
and is positive on [0, θ3], ii)
∫∞
−∞ | log f(t,θ)|f(t)dt < +∞ . Second, following
the results of Wald (1949), we have E log f(T,θ) < E log f(T,θ0) for any θ 6= θ0
where θ0 is the true parameter values. Therefore, the condition 1 holds. Third,
let Ωc denote the constrained parameter space, then Ωc is a closed subset of the
3-dimensional parameter space. Fourth, through detailed calculation, we can show
E{( ∂
∂θi
) log f(T |θ)} = 0 for i = 1, 2, 3.
From the results of Lemma 1 and Wald (1949), the MLEs θ̂n = (θ̂1n, θ̂2n, θ̂3n) exist
and are consistent.
To derive the limiting distributions of the MLEs, we need to apply the results
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from the special cases. When θ3 = θ3(0) is known, utilizing the transformation
V =

T ; T ≤ 0 or T > θ3
T 2/θ1 ; 0 < T ≤ θ1
θ3 − (θ3 − T )2/(θ3 − θ1) ; θ1 < T ≤ θ3,
(A.11)
we create a random variable V resembling an exponential distribution as defined
in equation (2) of Yao (1986). Then, applying the results from Proposition 6 of
Yao (1986) and Lemma 2, we have the following result, {n(θ̂1:3 − θ1(0)), n
1
2 (θ̂2:3 −
θ2(0))} converges in distribution to a random vector (Z1, Z2) where Z1 and Z2 are
independent, Z1 is defined in Definition 3, Z2 is a normal random variable with mean
0 and variance m−122 . We already know θ̂1 is a consistent estimator of θ1, applying
Lemma 5 of Chernoff and Rubin (1956), we derive the following result
θ̂1(n) − θ̂1:3 = o(n−1),
θ̂2 follows the classical MLE result:




n(θ̂1(n) − θ1(0)) = n(θ̂1(n) − θ̂1:3) + n(θ̂1:3 − θ1(0)),
n
1
2 (θ̂2(n) − θ2(0)) = n
1
2 (θ̂2(n) − θ̂2:3) + n
1
2 (θ̂2:3 − θ2(0)).
Then, we prove the following result,
θ̂1(n) − θ1(0) ≤p n−1, (A.12)
θ̂2(n) − θ2(0) ≤p n−
1
2 . (A.13)
We also show the limiting distribution of {n(θ̂1(n) − θ1(0)), n
1
2 (θ̂2(n) − θ2(0))} is the
same as {n(θ̂1:3−θ1(0)), n
1




converges in distribution to a random vector (Z1, Z2) where Z1 and Z2 are indepen-
dent, Z1 is defined in Definition 3, Z2 is normal random variables with mean 0 and
variance m−122 .
When θ1 = θ1(0) is known, we show that the PDF f(t|θ) resembles a truncated
reverse Weibull distribution because f(t|θ) 6= 0 only when 0 < t ≤ θ3. We say
a random variable T has a reverse Weibull distribution if T = −X + 2µ where
X is a random variable following a three-parameter Weibull distribution with CDF
Fx(x) = 1−exp[−(x−µα )
γ]. In our model, the PDF f(t,θ) resembles a reverse Weibull
distribution as t approaches the upper boundary θ3.
Applying the results from Theorem 1 and Theorem 3 of Smith (1985), we have
the following results : {n 12 (θ̂2:1− θ2(0)), (n log n)
1
2 (θ̂3:1− θ3(0))} converges in distribu-
tion to a random vector (Z2, Z3) where Z2 and Z3 are independent, Z2 and Z3 are
normal random variables with common mean 0 and respective variances m−122 and
m−133 . Furthermore,
θ̂2(n) − θ̂2:1 ≤p (n log n)−
1
2 ,






2 (θ̂2(n) − θ2(0)) = n
1
2 (θ̂2(n) − θ̂2:1) + n
1
2 (θ̂2:1 − θ2(0)),
(n log n)
1
2 (θ̂3(n) − θ3(0)) = (n log n)
1
2 (θ̂3(n) − θ̂3:1) + (n log n)
1
2 (θ̂3:1 − θ3(0)).
Then, we prove the following result,
θ̂2(n) − θ2(0) ≤p n−
1
2 ,




We also show the limiting distribution of {n 12 (θ̂2(n) − θ2(0)), (n log n)
1
2 (θ̂3(n) −
θ3(0))} is the same as {n
1
2 (θ̂2:1 − θ2(0)), (n log n)
1
2 (θ̂3:1 − θ3(0))}. Therefore,{n
1
2 (θ̂2(n) −
θ2(0)), (n log n)
1
2 (θ̂3(n) − θ3(0))} converges in distribution to a random vector (Z2, Z3)
where Z2 and Z3 are independent, Z2 and Z3 are normal random variables with
common mean 0 and respective variances m−122 and m
−1
33 .
It remains to show that n(θ̂1(n)− θ1(0)) and (n log n)
1
2 (θ̂3(n)− θ3(0)) are asymptoti-
cally independent. Since results in (3.18) and (3.20), it suffices to show n(θ̂1:3−θ1(0))
and (n log n)
1
2 (θ̂3:1 − θ3(0)) are asymptotically independent. Since Z1 follows a dis-
tribution of two independent random walks with each random walk as a sum of iid
exponential random variables, Z1 has a distribution without a Gaussian component.
Z3 is normal, following the result from Remark 1 of Smith (1985), Z1 and Z3 are
independent. The proof of Theorem 4 is complete.
Proof of Corollary 2: It is similar to the proof of Theorem 2 with the following
modifications.
To prove item 2, let θ3 → +∞, assume θ1 not approaching T1, then there ex-
ists some r > 1 such that θ1 approach Tr. We can deduce contradiction from
















))1−Ci < exp(− θ2
2
)1−Ci . In either case, for large enough θ3, Lk(Tr, θ3) <
Lk(T1, θ3), which contradicts that Tr(r > 1) is the MLE of θ1. Thus, r̂(θ2, θ3) = 1.
To prove item 3, if θ3 = Tk, assume θ1 6= Tk, then there exists a term θ3 − Tk =
Tk − Tk = 0 in either (K − 1 + S0)1−Ci part of the likelihood function Lk(θ1, θ3) or
(θ3−Tk)Ci part of likelihood function such that Lk(θ) = 0, therefore, θ1 = Tk. Thus,
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